<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">101984</article-id>
<article-id pub-id-type="doi">10.7554/eLife.101984</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.101984.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.4</article-version>
</article-version-alternatives>
<article-categories><subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The ESCRT protein CHMP5 restricts bone formation by controlling endolysosome-mitochondrion-mediated cell senescence</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhang</surname>
<given-names>Fan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Yuan</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Luyang</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chunjie</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Deping</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Haibo</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Ren</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haynes</surname>
<given-names>Cole M</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Shim</surname>
<given-names>Jae-Hyuck</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
<email>Jaehyuck.shim@umassmed.edu</email>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1291-2096</contrib-id>
<name>
<surname>Ge</surname>
<given-names>Xianpeng</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<aff id="a1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013xs5b60</institution-id><institution>Xuanwu Hospital Capital Medical University</institution></institution-wrap>, <city>Beijing</city>, <country country="CN">China</country></aff>
<aff id="a2"><label>2</label><institution>National Clinical Research Center for Geriatric Diseases</institution>, <city>Beijing</city>, <country country="CN">China</country></aff>
<aff id="a3"><label>3</label><institution>Joint Therapeutics Co. Ltd.</institution>, <city>Beijing</city>, <country country="CN">China</country></aff>
<aff id="a4"><label>4</label><institution>Beijing Citident Hospital of Stomatology</institution>, <city>Beijing</city>, <country country="CN">China</country></aff>
<aff id="a5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School</institution></institution-wrap>, <city>Worcester</city>, <country country="US">United States</country></aff>
<aff id="a6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0006swh35</institution-id><institution>The First Affiliated Hospital of Xiamen University-ICMRS Collaborating Center for Skeletal Stem Cells, State Key Laboratory of Cellular Stress Biology, Faculty of Medicine and Life Sciences, School of Medicine, Xiamen University</institution></institution-wrap>, <city>Xiamen</city>, <country country="CN">China</country></aff>
<aff id="a7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Medicine/Division of Rheumatology, University of Massachusetts Chan Medical School</institution></institution-wrap>, <city>Worcester</city>, <country country="US">United States</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Wan</surname>
<given-names>Mei</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Johns Hopkins University</institution>
</institution-wrap>
<city>Baltimore</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Shoback</surname>
<given-names>Dolores</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of California, San Francisco</institution>
</institution-wrap>
<city>San Francisco</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label><email>xianpeng.ge@xwhosp.org</email>; <email>xpge@penggegroup.com</email></corresp>
<fn id="n1" fn-type="equal"><label>#</label><p>These authors contributed equally to this work.</p></fn>
<fn fn-type="coi-statement"><p>Competing interests: The study started when the corresponding author (X. Ge) worked at the University of Massachusetts Medical School and a previous manuscript related to this study was posted on bioRxiv (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/2020.08.03.233874">https://doi.org/10.1101/2020.08.03.233874</ext-link>). To complete the study for a peer-reviewed publication, the co-first authors and X. Ge generated a novel Chmp5-floxed mouse strain, re-established all animal and cell models in the current laboratory in Beijing, China, and added novel critical experiments to make the conclusion convincing and the study comprehensive. Therefore, we reorganized the data and wrote it as a new paper. All authors agree on the current version of the paper, including its authorship and conclusions. J.H.S. is a scientific co-founder of AAVAA Therapeutics and holds equity in this company but does not have conflicts of interest with this study. Other authors declare no competing interests.</p></fn>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-11-19">
<day>19</day>
<month>11</month>
<year>2024</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2025-05-23">
<day>23</day>
<month>05</month>
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP101984</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-08-29">
<day>29</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-09-05">
<day>05</day>
<month>09</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.08.03.233874"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2024-11-19">
<day>19</day>
<month>11</month>
<year>2024</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.101984.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.101984.1.sa4">eLife Assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101984.1.sa3">Reviewer #1 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101984.1.sa2">Reviewer #2 (Public review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.101984.1.sa1">Reviewer #3 (Public review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.101984.1.sa0">Author response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Zhang et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhang et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-101984-v2.pdf"/>
<abstract>
<title>Abstract</title><p>The dysfunction of the cellular endolysosomal pathway, such as in lysosomal storage diseases, can cause severe musculoskeletal disorders. However, how endolysosomal dysfunction causes musculoskeletal abnormalities remains poorly understood, limiting therapeutic options. Here, we report that CHMP5, a member of the endosomal sorting complex required for transport (ESCRT)-III protein family, is essential to maintain the endolysosomal pathway and regulate bone formation in osteogenic lineage cells. Genetic ablation of <italic>Chmp5</italic> in mouse osteogenic cells increases bone formation in vivo and in vitro. Mechanistically, <italic>Chmp5</italic> deletion causes endolysosomal dysfunction by decreasing the VPS4A protein, and CHMP5 overexpression is sufficient to increase the VPS4A protein. Subsequently, endolysosomal dysfunction disturbs mitochondrial functions and increases mitochondrial ROS, ultimately resulting in skeletal cell senescence. Senescent skeletal cells cause abnormal bone formation by combining cell-autonomous and paracrine actions. Importantly, the elimination of senescent cells using senolytic drugs can alleviate musculoskeletal abnormalities in <italic>Chmp5</italic> conditional knockout mice. Therefore, our results show that cell senescence represents an underpinning mechanism and a therapeutic target for musculoskeletal disorders caused by the aberrant endolysosomal pathway, such as in lysosomal storage diseases. These results also uncover the function and mechanism of CHMP5 in the regulation of cell senescence by affecting the endolysosomal-mitochondrial pathway.</p>
</abstract>
<custom-meta-group>
<custom-meta specific-use="meta-only">
<meta-name>publishing-route</meta-name>
<meta-value>prc</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Based on the manuscript uploaded earlier, minor revisions were made to Figure 3 and its legend. Sorry for the inconvenience.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The endosomal sorting complex required for transport (ESCRT) machinery is an evolutionarily conserved molecular mechanism essential for diverse cell biological processes. Since it was initially discovered in the early 21st century in the budding yeast <italic>Saccharomyces cerevisiae</italic>, the molecular gear has been extensively dissected in the endocytic pathway, which sorts ubiquitinated membrane proteins and bound cargoes that commit to lysosomal degradation [<xref ref-type="bibr" rid="c1">1</xref>–<xref ref-type="bibr" rid="c4">4</xref>]. In addition to the endocytic process, ESCRT proteins also play critical roles in other cell activities, such as exocytosis, viral budding, cytokinesis, pruning of neurons, repair of the plasma membrane, and assembly of the nuclear envelope [<xref ref-type="bibr" rid="c2">2</xref>, <xref ref-type="bibr" rid="c4">4</xref>]. In the endocytic pathway, the ESCRT machinery consists of a series of functionally overlapping protein complexes, including ESCRT-0, -I, -II and -III. While the ESCRT-0, -I, and -II complexes are mainly responsible for protein sorting and recruiting ESCRT-III components, the ESCRT-III complex, cooperating with the ATPase VPS4, is the primary executor of membrane severing during the formation of multivesicular bodies (MVB) [<xref ref-type="bibr" rid="c3">3</xref>, <xref ref-type="bibr" rid="c5">5</xref>], which ultimately fuse with the lysosomes for cargo degradation or with the plasma membrane to release cargos into the extracellular space.</p>
<p>Charged multivesicular body protein 5 (CHMP5), the mammalian ortholog of yeast VPS60/MOS10, is a component of the ESCRT-III protein complex and plays an essential role in the late stage of MVB formation [<xref ref-type="bibr" rid="c6">6</xref>]. As the yeast <italic>Vps60/Mos10</italic>-null mutation disturbs the endosome-to-vacuole (the lysosome-like structure in yeast) trafficking and affects the sorting of internalized endocytic markers [<xref ref-type="bibr" rid="c7">7</xref>], ablation of <italic>Chmp5</italic> in mouse embryonic fibroblasts (MEFs) also affects the sorting from late endosomes/MVBs to lysosomes and reduces lysosomal degradation of multiple activated receptors [<xref ref-type="bibr" rid="c6">6</xref>]. Notably, in mouse osteoclasts, CHMP5 suppresses ubiquitylation of the IκBα protein and restricts the activity of NFκB pathway, without any effect on endolysosomal functions [<xref ref-type="bibr" rid="c8">8</xref>]. During αβ T lymphocyte development, CHMP5 promotes thymocyte survival by stabilizing the pro-survival protein of BCL2 and does not have an influence on the endolysosomal system [<xref ref-type="bibr" rid="c9">9</xref>]. These studies suggest that the regulation of the endolysosomal pathway by CHMP5 depends on the cell and tissue context.</p>
<p>The dysfunction of the endolysosomal pathway can cause severe musculoskeletal disorders. A such example is lysosomal storge diseases, which include more than 50 different subgroups of diseases due to mutations in genes that encode lysosomal hydrolases or genes that are responsible for the transport, maturation, and functions of lysosomal hydrolases [<xref ref-type="bibr" rid="c10">10</xref>]. Musculoskeletal pathologies, such as joint stiffness/contracture, bone deformation, muscular atrophy, short stature, and decreased mobility, are among the most common, in some cases the earliest, clinical presentations of lysosomal storage diseases [<xref ref-type="bibr" rid="c11">11</xref>, <xref ref-type="bibr" rid="c12">12</xref>]. These musculoskeletal lesions are particularly refractory to current treatments for lysosomal storage diseases, including enzyme replacement treatment and hematopoietic stem cell transplantation [<xref ref-type="bibr" rid="c13">13</xref>]. Therefore, studies on the mechanisms of musculoskeletal pathologies due to endolysosomal dysfunction are paramount to design and develop novel treatments for these disorders.</p>
<p>In this study, our results uncover the function and mechanism of CHMP5 in the regulation of cell senescence and bone formation in osteogenic cells. Deletion of <italic>Chmp5</italic> causes endolysosomal dysfunction involving decreased VPS4A protein and subsequently activates cell senescence by increasing intracellular mitochondrial ROS. Senescent cells induce bone formation in both autonomous and paracrine ways. Importantly, senolytic treatment is effective in mitigating musculoskeletal pathologies caused by <italic>Chmp5</italic> deletion.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Ablation of <italic>Chmp5</italic> in mouse osteogenic lineage cells causes aberrant bone formation</title>
<p>In addition to the well-characterized role of the CTSK gene in osteoclasts, this gene has recently been reported to identify periskeletal progenitors [<xref ref-type="bibr" rid="c14">14</xref>–<xref ref-type="bibr" rid="c16">16</xref>]. In particular, the ablation of <italic>Chmp5</italic> in mouse <italic>Ctsk</italic>-expressing cells (hereafter referred to as <italic>Chmp5<sup>Ctsk</sup></italic> mice, homozygous) caused dramatic periskeletal bone overgrowth near the joint compared to <italic>Chmp5<sup>Ctsk/+</sup></italic> (heterozygous) and <italic>Chmp5<sup>fl/fl</sup></italic> littermate controls (<xref rid="fig1" ref-type="fig">Fig. 1A</xref> and <xref rid="fig1" ref-type="fig">B</xref>). Aberrant periskeletal bone growth in <italic>Chmp5<sup>Ctsk</sup></italic> mice became distinct around postnatal day 10 (d10), progressed with age, and involved multiple bones and joints throughout the body, including knee, ankle, and foot joints (<xref rid="fig1" ref-type="fig">Fig. 1A to C</xref> and <xref rid="figs1" ref-type="fig">Fig. S1A</xref>). With age, these animals developed severe skeletal deformities, progressive joint stiffness, reduced motility, and short stature. Despite bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> animals, mechanical tests showed that bone stiffness and fracture stress decreased significantly (<xref rid="fig1" ref-type="fig">Fig. 1D</xref>), suggesting that bone mechanical properties were impaired in <italic>Chmp5<sup>Ctsk</sup></italic> mice.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 1.</label>
<caption><title>Ablation of <italic>Chmp5</italic> in mouse osteogenic lineage cells causes aberrant bone formation.</title>
<p>(<bold>A</bold>) Micro-CT and H&amp;E staining showing periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice in comparison with <italic>Chmp5<sup>fl/fl</sup></italic> mice at 7 weeks of age. Dot line representing the approximate bone border. <italic>n</italic> = 10 animals per group. (<bold>B</bold>) Micro-CT images displaying periskeletal overgrowth in the ankle and foot in <italic>Chmp5<sup>Ctsk</sup></italic> versus <italic>Chmp5<sup>fl/fl</sup></italic> mice at one year of age. <italic>n</italic> = 4 animals per group. (<bold>C</bold>) Alizarin red staining of skeletal preparations on postnatal day 10. <italic>n</italic> = 4 mice per group, arrows indicating periskeletal bone overgrowth. (<bold>D</bold>) Three-point test showing femur bone stiffness and ultimate stress (fracture stress) in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>fl/fl</sup></italic> mice. <italic>n</italic> = 5 male animals per group. Similar changes observed in both sexes. (<bold>E</bold>) Confocal images mapping <italic>Ctsk</italic><sup>+</sup> (GFP<sup>+</sup>) progenitors in periskeletal tissues in <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice at 2 weeks of age. Asterisks indicating periskeletal overgrowths; dot-line representing the approximate bone border. <italic>n</italic> = 4 animals each group. (<bold>F</bold>) X-ray images demonstrating progressive cortical bone expansion (arrows) and decreased skeletal muscle mass (asterisks) in <italic>Chmp5<sup>Dmp1</sup></italic> in comparison with <italic>Chmp5<sup>fl/fl</sup></italic> mice. <italic>n</italic> = 3, 3, 10, 8 animals per group for 3 weeks, 5 weeks, 10 weeks, and 1 year of age, respectively. (<bold>G</bold>) Micro-CT analyses displaying cortical bone expansion in <italic>Chmp5<sup>Dmp1</sup></italic> relative to <italic>Chmp5<sup>fl/fl</sup></italic> mice at 10 weeks of age. <italic>n</italic> = 6 <italic>Chmp5<sup>fl/fl</sup></italic> and 5 <italic>Chmp5<sup>Dmp1</sup></italic> male mice, similar changes found in both genders. (<bold>H</bold>) Skeletal muscle mass in <italic>Chmp5<sup>Dmp1</sup></italic> compared to <italic>Chmp5<sup>fl/fl</sup></italic> mice at 10-12 weeks of age. <italic>n</italic> = 4 animals (male) per group, similar changes found in both genders. (<bold>I</bold>) Hindlimb abduction of <italic>Chmp5<sup>Dmp1</sup></italic> mice in comparison with <italic>Chmp5<sup>fl/fl</sup></italic> littermate controls at 10 weeks of age. More than 20 animals per group observed. (<bold>J</bold>) Four-limb handing time (<italic>n</italic> = 10 per group, pooled data from both sexes), and forelimb pull strength (<italic>n</italic> = 6 per group, male mice) in <italic>Chmp5<sup>Dmp1</sup></italic> compared to <italic>Chmp5<sup>fl/fl</sup></italic> mice at 10-12 weeks of age. Similar changes found in both genders. All data are mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test. Scale bars, 1 mm for micro-CT and skeletal preparation images, 200 μm for histological images, and 10 mm in panel (<bold>F</bold>).</p></caption>
<graphic xlink:href="233874v4_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>To track CTSK<sup>+</sup> periskeletal progenitors during the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice, we crossed <italic>Ctsk-Cre</italic>, <italic>Chmp5<sup>fl/fl</sup></italic>, and <italic>Rosa26<sup>mTmG</sup></italic> mice to generate <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> reporter animals, in which CTSK<sup>+</sup> periskeletal progenitors and their descendants express membrane-localized green fluorescence protein (GFP). In <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> control mice, GFP<sup>+</sup> cells could be detected in the perichondrium, groove of Ranvier, periosteum, ligament, and enthesis in addition to osteoclasts in the bone marrow, but not in growth plate chondrocytes (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>). With <italic>Chmp5</italic> deletion, GFP<sup>+</sup> cells consisted of a major part of cells in periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice (<xref rid="fig1" ref-type="fig">Fig. 1E</xref> and <xref rid="figs1" ref-type="fig">Fig. S1B</xref>). Tartarate resistant acid phosphatase (TRAP) staining did not show TRAP<sup>+</sup> osteoclasts in the periskeletal lesion, while obvious TRAP<sup>+</sup> osteoclasts could be detected in the bone marrow (<xref rid="figs1" ref-type="fig">Fig. S1C</xref>). These results indicate that <italic>Chmp5</italic>-deficient periskeletal progenitors directly contribute to the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice.</p>
<p>Next, we sought to confirm the role of CHMP5 in the regulation of bone formation by deleting this gene using another mouse line of osteogenic lineage Cre. We crossed <italic>Chmp5<sup>fl/fl</sup></italic> mice with the line of <italic>Prrx1</italic>-Cre [<xref ref-type="bibr" rid="c17">17</xref>], <italic>Col2</italic>-Cre [<xref ref-type="bibr" rid="c18">18</xref>] or <italic>Osx</italic>-Cre [<xref ref-type="bibr" rid="c19">19</xref>] mice to delete the <italic>Chmp5</italic> gene in <italic>Prrx1</italic>-expressing limb mesenchymal progenitors (<italic>Chmp5<sup>Prrx1</sup></italic> mice), <italic>Col2</italic>-expressing perichondral progenitors (<italic>Chmp5<sup>Col2</sup></italic> mice) or <italic>Osx</italic>-expressing osteoprogenitors (<italic>Chmp5<sup>Osx</sup></italic> mice) and were unable to obtain postnatal homozygous gene knockout mice, probably due to embryonic lethality after ablating C<italic>hmp5</italic> expression in these osteogenic lineages. Subsequently, we used the <italic>Dmp1</italic>-Cre mouse line that could target postnatal endosteal osteoprogenitors, preosteoblasts, mature osteoblasts, and osteocytes [<xref ref-type="bibr" rid="c20">20</xref>–<xref ref-type="bibr" rid="c22">22</xref>]. <italic>Chmp5<sup>Dmp1</sup></italic> mice were born in normal Mendelian ratios and were viable. Within three weeks of age, the skeletons of <italic>Chmp5<sup>Dmp1</sup></italic> mice began to show a distinct expansion in comparison with <italic>Chmp5<sup>Dmp1/+</sup></italic> and <italic>Chmp5<sup>fl/fl</sup></italic> littermate controls, which progressed with age and became much more severe at 1 year of age (<xref rid="fig1" ref-type="fig">Fig. 1F</xref>). Bone expansion in <italic>Chmp5<sup>Dmp1</sup></italic> mice that occurred mainly in the endosteum was further shown in detail around the age of 10 weeks by micro-CT and histological analyses (<xref rid="fig1" ref-type="fig">Fig. 1G</xref> and <xref rid="figs1" ref-type="fig">Fig. S1D, E</xref>).</p>
<p>Meanwhile, since <italic>Dmp1</italic>-expressing lineage cells also generate skeletal muscle cells [<xref ref-type="bibr" rid="c21">21</xref>], <italic>Chmp5<sup>Dmp1</sup></italic> mice showed a profound decrease in skeletal muscle mass with age (<xref rid="fig1" ref-type="fig">Fig. 1F</xref> and <xref rid="fig1" ref-type="fig">H</xref>). Hindlimb abduction, full-limb hanging time, and front-limb pull strength tests showed that muscular functions also decreased profoundly in <italic>Chmp5<sup>Dmp1</sup></italic> compared to <italic>Chmp5<sup>fl/fl</sup></italic> mice (<xref rid="fig1" ref-type="fig">Fig. 1I</xref> and <xref rid="fig1" ref-type="fig">J</xref>).</p>
</sec>
<sec id="s2b">
<title>CHMP5 restricts osteogenesis in skeletal progenitor cells</title>
<p>To further characterize the function of CHMP5 in the regulation of bone formation, we cultured and sorted <italic>Ctsk</italic>-expressing periskeletal progenitor cells (CD45<sup>−</sup>;CD31<sup>−</sup>;GFP<sup>+</sup>) from periskeletal tissues of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice in the early stage of skeletal lesions (P10-P14) (<xref rid="fig2" ref-type="fig">Fig. 2A</xref> and <xref rid="figs2" ref-type="fig">Fig. S2A, B</xref>, hereafter referred to as <italic>Chmp5<sup>Ctsk/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors, respectively). <italic>Chmp5</italic> deletion in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors was confirmed by gene expression analysis (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>). Strikingly, when cultured in the osteogenic differentiation medium, <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors showed considerably enhanced osteogenesis in comparison with <italic>Chmp5<sup>Ctsk/+</sup></italic> control cells, as shown by alizarin red staining, von Kosaa staining, and alkaline phosphatase activity assay (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 2.</label>
<caption><title>CHMP5 restricts osteogenesis in skeletal progenitor cells.</title>
<p>(<bold>A</bold>) Flow cytometry showing the strategy for sorting CD45<sup>−</sup>;CD31<sup>−</sup>;GFP<sup>+</sup> and CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-periskeletal progenitors from periskeletal tissues of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice at 2 weeks of age. <italic>n</italic> = 10 mice per group. (<bold>B</bold>) Quantitative PCR determining the expression of <italic>Chmp5</italic> in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 6 mice per group. (<bold>C</bold>) Alizarin red staining, von Kossa staining and alkaline phosphatase activity assay determining osteogenesis in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 3 replicates each group, representative results of cells from 3 different mice per group. (<bold>D</bold>) Western blot confirming <italic>Chmp5</italic> deletion in mouse MC3T3-E1 cells by lentiviral CRISPR/CAS9. (<bold>E</bold>) Alizarin red staining demonstrating osteogenesis in MC3T3-E1 cells with or without <italic>Chmp5</italic> deletion by lentiviral CRISPR/CAS9. <italic>n</italic> = 4 replicates per group, experiments repeated twice for each time point. <bold>(F)</bold> Ingenuity pathway analysis of RNA-seq data showing increased activity of osteoblast differentiation in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. All data are mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="233874v4_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>The regulation of osteogenesis by CHMP5 in skeletal progenitors was further determined in the osteogenic cell line MC3T3-E1 after removing <italic>Chmp5</italic> using CRISPR/CAS9 technology (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>). The deletion of <italic>Chmp5</italic> in MC3T3-E1 cells also markedly increased osteogenesis, as shown by alizarin red staining at 2 weeks and 3 weeks of osteogenic induction (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). Consistently, the ingenuity pathway analysis of RNA-seq data of <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors showed that multiple molecular pathways related to osteoblast differentiation were activated with the <italic>Chmp5</italic> deletion (<xref rid="fig2" ref-type="fig">Fig. 2F</xref>). Taken together, these results reveal a function of CHMP5 in regulating osteogenesis in skeletal progenitors.</p>
</sec>
<sec id="s2c">
<title>CHMP5 controls skeletal progenitor cell senescence</title>
<p>To gain more insight into the mechanism of regulation of bone formation by CHMP5, we assumed that depletion of <italic>Chmp5</italic> in osteogenic lineage cells also increases cell proliferation, which contributes to the bone overgrowth in <italic>Chmp5</italic> conditional knockout mice. Unexpectedly, <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors showed a significant decrease in the cell proliferation rate compared to <italic>Chmp5<sup>Ctsk/+</sup></italic> controls (approximately 58% decrease in the cell number on day 6 of P2 culture, <xref rid="fig3" ref-type="fig">Fig. 3A</xref>). Because CHMP5 has been reported to regulate thymocyte apoptosis [<xref ref-type="bibr" rid="c9">9</xref>], we performed cell apoptosis analyses for <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> cells. Annexin V staining showed that approximately 4.96 ± 0.81% of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors vs. 1.69 ± 0.68% of <italic>Chmp5<sup>Ctsk/+</sup></italic> control cells were positively stained (<xref rid="figs3" ref-type="fig">Fig. S3A</xref>). Similarly, the in-situ terminal deoxynucleotidyl transferase dUTP nick end labelling assay (TUNEL) demonstrated that around 3.70 ± 0.72% cells in the periskeletal lesion of <italic>Chmp5<sup>Ctsk</sup></italic> mice were positively labelled (<xref rid="figs3" ref-type="fig">Fig. S3B</xref>). These results show that cell apoptosis is activated in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors in a rather low ratio.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 3.</label>
<caption><title>CHMP5 controls skeletal progenitor cell senescence.</title><p>(<bold>A</bold>) Cell number counting and AlamarBlue assay determining cell proliferation in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors from 2-week-old animals. <italic>n</italic> = 3 replicates per group per time point; experiments repeated 3 times using cells from 3 different mice. (<bold>B</bold>) Volcano plot of RNA-seq data showing differentially expressed genes in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 3 per group with cells from 3 different animals. (<bold>C</bold>) ConsensusPathDB gene set enrichment analysis of RNA-seq data showing positive enrichment of genes in multiple molecular pathways related to cell senescence (Reactome) in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. (<bold>D</bold>) Western blot determining the expression of p16 and p21 proteins in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> (control) periskeletal progenitors. The numbers above lanes indicating the intensity of the p16 or p21 band relative to that of <italic>Control</italic> cells after normalization by β-Actin. Results repeated 3 times with cells from 3 different animals. (<bold>E</bold>) Immunostaining of γH2AX and quantification of γH2AX<sup>+</sup>;GFP<sup>+</sup> cells in the periosteum and periskeletal overgrowth in <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice, respectively. <italic>n</italic> = 3 with tissues from 3 different animals per group. Scale bars, 100 μm; arrows indicating the periosteum. (<bold>F</bold>) Gross image demonstrating aging-related phenotypes in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>Chmp5<sup>Ctsk/+</sup></italic> mice at 1 year of age. Images are representative of 5 animals per group. (<bold>G</bold>) Cell cycle analysis in ATDC5 cells with or without <italic>Chmp5</italic> deletion. <italic>n</italic> = 3 replicates per group, results repeated twice. All data are mean ± s.d.; 2-way ANOVA followed by multiple comparisons or two-tailed unpaired Student’s <italic>t</italic>-test (E).</p></caption>
<graphic xlink:href="233874v4_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Notably, the low apoptotic cell ratio (approximately 5%) could not well match the decrease in cell proliferation rate (approximately 58%) in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors. We further analyzed the RNA-seq data of <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> cells to dig out the mechanism of CHMP5 deficiency on the fate of skeletal progenitors. The gene set enrichment analysis (GSEA) showed significant enrichment of genes in multiple Reactome molecular pathways associated with cell senescence in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors, including <italic>Hmga1</italic>, <italic>Hmga2</italic>, <italic>Trp53</italic>, <italic>Ets1</italic>, and <italic>Txn1</italic> (<xref rid="fig3" ref-type="fig">Fig. 3B</xref> and <xref rid="fig3" ref-type="fig">C</xref>). Meanwhile, GSEA of RNA-seq data also showed significant enrichment of the SAUL_SEN_MAYO geneset (positively correlated with cell senescence) and the KAMMINGA_SENESCENCE geneset (negatively correlated with cellular senescence) in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors (<xref rid="figs3" ref-type="fig">Fig. S3C</xref>).</p>
<p>Furthermore, Western blot results showed that both the p16 and p21 proteins, two canonical markers of cellular senescence, were upregulated in <italic>Chmp5<sup>Ctsk</sup></italic> compared to control cells, with a higher degree of upregulation in the p16 protein (<xref rid="fig3" ref-type="fig">Fig. 3D</xref>). However, the mRNA levels of <italic>Cdkn2a</italic> (p16) and <italic>Cdkn1a</italic> (p21) did not show significant changes according to the RNA-seq analysis (<xref rid="figs3" ref-type="fig">Fig. S3D</xref>). Furthermore, immunostaining for another cell senescence marker γH2Ax demonstrated that there were significantly more γH2Ax<sup>+</sup>;GFP<sup>+</sup> cells in periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic>;<italic>Rosa26<sup>mTmG/+</sup></italic> mice relative to the periosteum of <italic>Chmp5<sup>Ctsk/+</sup></italic>;<italic>Rosa26<sup>mTmG/+</sup></italic> control mice (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>). Accordingly, C<italic>hmp5<sup>Ctsk</sup></italic> mice showed gross accelerated aging-related phenotypes, including hair loss, joint stiffness/contracture, and decreased motility (<xref rid="fig3" ref-type="fig">Fig. 3F</xref>).</p>
<p>To further characterize the effect of CHMP5 on skeletal progenitor cell fate, we deleted <italic>Chmp5</italic> in ATDC5 cells, which were shown to be an appropriate model of periskeletal progenitors in a previous study [<xref ref-type="bibr" rid="c23">23</xref>], using CRISPR/CAS9 technology (<xref rid="figs3" ref-type="fig">Fig. S3E</xref>). Similarly, <italic>Chmp5</italic> deletion also significantly suppressed the cell proliferation rate of ATDC5 cells and mildly increased cell apoptosis (<xref rid="figs3" ref-type="fig">Fig. S3F and G</xref>). However, inhibition of cell apoptosis using the pancaspase inhibitor Q-VD-Oph could not reverse cell number reduction (<xref rid="figs3" ref-type="fig">Fig. S3H</xref>), indicating that cell apoptosis was not the main cause of the decrease in the proliferation rate of <italic>Chmp5</italic>-deficient skeletal progenitors. Instead, cell cycle analysis showed a significant decrease of <italic>Chmp5</italic>-deficient ATDC5 cells in phase S, and a significant proportion of these cells were arrested in G0/G1 or G2/M phases (<xref rid="fig3" ref-type="fig">Fig. 3G</xref>), which is a typic characteristic of cell cycle arrest in senescent cells. Taken together, these results at molecular, cellular, and gross levels demonstrate that <italic>Chmp5</italic> deficiency induces skeletal progenitor cell senescence.</p>
</sec>
<sec id="s2d">
<title>Secretory phenotype of <italic>Chmp5</italic>-deficient skeletal progenitors</title>
<p>A remarkable feature of senescent cells is the senescence associated secretory phenotype (SASP), which plays a critical role in mediating the pathophysiological processes of cell senescence [<xref ref-type="bibr" rid="c24">24</xref>]. In particular, periskeletal overgrowths in <italic>Chmp5<sup>Ctsk</sup></italic>;<italic>Rosa26<sup>mTmG/+</sup></italic> mice showed evident integration of many cells lacking evidence of Cre-mediated recombination (GFP<sup>−</sup>) (<xref rid="fig1" ref-type="fig">Fig. 1E</xref>), suggesting that <italic>Chmp5</italic>-deleted periskeletal progenitors might recruit neighboring <italic>wild-type</italic> cells to facilitate the bone overgrowth. Additionally, the GSEA of RNA-seq data showed a significant enrichment of genes associated with the SASP molecular pathway in <italic>Chmp5</italic>-deleted periskeletal progenitors (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>). Meanwhile, confocal fluorescence microscopy captured many extracellular vesicles shed from the plasma membrane of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors, which were rarely detected around <italic>wild-type</italic> control cells (<xref rid="fig4" ref-type="fig">Fig. 4B</xref>). Furthermore, nanoparticle tracking analysis demonstrated higher concentrations of extracellular vesicles in the culture medium of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors compared to <italic>wild-type</italic> control cells (<xref rid="fig4" ref-type="fig">Fig. 4C, D</xref> and <xref rid="figs4" ref-type="fig">Fig. S4A</xref>). These results show that <italic>Chmp5</italic> deficiency activates the SASP molecular pathway and increases the secretion of skeletal progenitors.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 4.</label>
<caption><title>Secretory phenotype of <italic>Chmp5</italic>-deficient skeletal progenitors.</title><p>(<bold>A</bold>) GSEA of RNA-seq data showing positive enrichment of genes associated with the molecular pathway of senescence-associated secretory phenotype (Reactome database) in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. (<bold>B</bold>) Confocal images showing and quantifying extracellular vesicles (arrowheads) around <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors. Images are representative of 30 cells from 3 animals per group. Scale bars, 10 μm. (<bold>C</bold> and <bold>D</bold>) Nanoparticle tracking analysis of extracellular vesicles in culture medium of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors. Data pooled from 3 replicates per group, 5 reads for each; repeated twice using cells from 2 mice per group. (<bold>E</bold>) Cell number counting determining cell proliferation in ATDC5 cells treated with culture supernatant from <italic>Chmp5</italic>-deficient or <italic>Chmp5</italic>-sufficient cells. <italic>n</italic> = 3 per group per time point, repeated twice. (<bold>F</bold> and <bold>G</bold>) Cell number counting and alizarin red staining examining cell proliferation (<bold>F</bold>) and osteogenesis (<bold>G</bold>) in neighboring CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-progenitors sorted from periskeletal tissues of <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> or <italic>Ctsk-Cre;Rosa26<sup>mTmG/+</sup></italic> mice. <italic>n</italic> = 3 replicates per group per time point, repeated 3 times using cells from 3 different animals. (<bold>H</bold>) Volcano plot showing differentially secreted protein in supernatants of <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors analyzed by Nano LC-MS/MS. <italic>n</italic> = 3 with cells from 3 different animals per group. (<bold>I</bold>) Western blot verifying the increase in COL1A1 and TAGLN proteins in supernatants of <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>wild-type</italic> periskeletal progenitors. Commas blue stain as the loading control. Results repeated 3 times using cells from 3 different mice each group. All data are mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test for comparison of two groups or 2-way ANOVA followed by multiple comparisons.</p></caption>
<graphic xlink:href="233874v4_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Functionally, conditioned medium collected from <italic>Chmp5</italic>-deficient skeletal progenitors caused a higher proliferation rate of ATDC5 cells than medium from control cells (<xref rid="fig4" ref-type="fig">Fig. 4E</xref>). Meanwhile, coculture of <italic>wild-type</italic> with <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors promoted osteogenesis of <italic>wild-type</italic> cells (<xref rid="figs4" ref-type="fig">Fig. S4B</xref>). Simultaneously, CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-skeletal progenitors from periskeletal tissues of <italic>Chmp5<sup>Ctsk</sup></italic>;<italic>Rosa26<sup>mTmG/+</sup></italic> mice showed increased proliferation along with enhanced osteogenic differentiation compared to the corresponding cells from <italic>Ctsk-Cre;Rosa26<sup>mTmG/+</sup></italic> control mice (<xref rid="fig4" ref-type="fig">Fig. 4F, G</xref> and <xref rid="figs4" ref-type="fig">Fig. S4C, D</xref>). Immunostaining for the cell proliferation marker Ki-67 demonstrated an increase in the number of stained cells in the periskeletal lesion of <italic>Chmp5<sup>Ctsk</sup></italic> mice (<xref rid="figs4" ref-type="fig">Fig. S4E</xref>). Since GFP<sup>+</sup> <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors showed a decreased cell proliferation rate and increased cell senescence (<xref rid="fig3" ref-type="fig">Fig. 3</xref>), and the GFP-<italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors showed an increased cell proliferation rate (<xref rid="fig4" ref-type="fig">Fig. 4F</xref> and <xref rid="figs4" ref-type="fig">Fig. S4C</xref>), these Ki-67<sup>+</sup> cells in <xref rid="figs4" ref-type="fig">Fig. S4E</xref> should represent GFP- skeletal progenitors in the periskeletal lesion. Together, these results demonstrate that <italic>Chmp5</italic>-deficient skeletal progenitors could promote the proliferation and osteogenesis of surrounding <italic>wild-type</italic> skeletal progenitors.</p>
<p>Next, we performed a secretome analysis to characterize secretory profiles of <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. Fifteen proteins were found to increase and five proteins to decrease in the cell supernatant of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors (<xref rid="fig4" ref-type="fig">Fig. 4H</xref> and <xref rid="figs4" ref-type="fig">Fig. S4F</xref>). In particular, all 15 upregulated proteins, including NCAM1, CSPG4, SDF4, NME2, TAGLN, OLFML2B, PXDN, COL4A1, FSTL1, TPI1, MFGE8, COL1A2, COL1A1, HSPG2, and COL3A1, have been identified in the osteoblastic cell secretome or in the regulation of osteoblast differentiation or functions [<xref ref-type="bibr" rid="c25">25</xref>, <xref ref-type="bibr" rid="c26">26</xref>]. Western blot verified upregulation of two of these proteins, COL1A1 and TAGLN, in the cell supernatant of <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors (<xref rid="fig4" ref-type="fig">Fig. 4I</xref>). Notably, the secretome analysis did not detect common SASP factors, such as cytokines and chemokines, in the secretory profile of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors, probably due to their small molecular weights and the technical limitations of the mass-spec analysis. Taken together, these results demonstrate a secretory phenotype and paracrine actions of <italic>Chmp5</italic>-deficient skeletal progenitors. However, factors that mediate the paracrine actions of <italic>Chmp5</italic>-deficient periskeletal progenitors remain further clarified in future studies.</p>
</sec>
<sec id="s2e">
<title>Senolytic treatment mitigates musculoskeletal pathologies in <italic>Chmp5</italic> conditional knockout mice</title>
<p>To affirm the role of cell senescence of osteogenic cells in contributing to bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice, we treated <italic>Chmp5</italic>-dificient periskeletal progenitors and animals with the senolytic drugs quercetin and dasatinib (Q + D), which have been widely used to eliminate senescent cells under various physiological and pathological conditions [<xref ref-type="bibr" rid="c27">27</xref>, <xref ref-type="bibr" rid="c28">28</xref>], and assessed the therapeutic efficacy. First, in vitro Q + D treatment showed that <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors were more sensitive to senolytic drugs for cell apoptosis compared to control cells (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>). <italic>Chmp5<sup>Ctsk</sup></italic> animals were then treated with Q + D from the first two weeks after birth for 7 weeks and showed a significantly improved periskeletal bone overgrowth and animal motility compared to <italic>Chmp5<sup>fl/fl</sup></italic> control animals (<xref rid="fig5" ref-type="fig">Fig. 5B</xref> and <xref rid="figs5" ref-type="fig">Fig. S5</xref>). Similarly, treatment of <italic>Chmp5<sup>Dmp1</sup></italic> mice with Q + D also improved musculoskeletal manifestations, including hindlimb abduction, the whole femur and cortical bone thickness, and partially restored skeletal muscle functions (<xref rid="fig5" ref-type="fig">Fig. 5C-E</xref>). An improvement in animal motility was also found with Q + D treatment in adult mice. There were no apparent abnormalities in <italic>Chmp5<sup>fl/fl</sup></italic> control animals treated with the same dose of Q + D in parallel.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 5.</label>
<caption><title>Senolytic treatment mitigates musculoskeletal pathologies in <italic>Chmp5</italic> conditional knockout mice.</title><p>(<bold>A</bold>) Incucyte live-cell apoptosis analysis of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors treated with 50 μM Quercetin and 500 nM dasatinib (Q + D) and labeled by Annexin V. <italic>n</italic> = 6 for each group, experiment repeated twice using cells from different animals. (<bold>B</bold>) Gross images, radiography, and histology (H&amp;E) respectively demonstrating hindlimb abduction and periskeletal bone overgrowth (arrows or dot-line) in <italic>Chmp5<sup>Ctsk</sup></italic> in comparison with <italic>Chmp5<sup>fl/fl</sup></italic> mice after treatment with Q + D or vehicle PEG400 weekly for 7 weeks. <italic>n</italic> = 8-10 mice per group. Continuous lines in H&amp;E images indicating an approximate edge of the cortical bone and dot lines indicating the edge of periskeletal overgrowing bones. Scale bars, 100 μm. (<bold>C</bold>) Four-limb hanging time and forelimb pull strength in <italic>Chmp5<sup>Dmp1</sup></italic> and <italic>Chmp5<sup>fl/fl</sup></italic> mice after treatment with Q + D or the vehicle PEG400 weekly for 16 weeks. <italic>n</italic> = 12 animals per group for hanging time test pooled from both genders; <italic>n</italic> = 7 male mice per group for the forelimb pull strength test, similar changes found in both genders. (<bold>D</bold>) Gross images showing hindlimb abduction in <italic>Chmp5<sup>Dmp1</sup></italic> compared to <italic>Chmp5<sup>fl/fl</sup></italic> mice after treatment with Q + D or the vehicle PEG400. <italic>n</italic> = 12 animals per group. (<bold>E</bold>) Gross image and Micro-CT analysis demonstrating femur and cortical bone thickness in <italic>Chmp5<sup>Dmp1</sup></italic> mice after treatment with Q + D or the vehicle PEG400. <italic>n</italic> = 5 male mice per group, similar changes found in both genders. Scale bar, 1 mm. (<bold>F</bold>) Micro-CT images showing periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> in comparison with <italic>Chmp5<sup>fl/fl</sup></italic> mice after treatment with ABT-263 or vehicle weekly for 8 weeks. <italic>n</italic> = 4 mice per group, Scale bars, 2 mm. All data are mean ± s.d.; 2-way ANOVA followed by multiple comparisons or two-tailed unpaired Student’s <italic>t</italic>-test for comparison of two groups.</p></caption>
<graphic xlink:href="233874v4_fig5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Furthermore, to verify the efficacy of senolytic drugs in treating the periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice, we used another senolytic drug Navitoclax (ABT-263), which is a BCL-2 family inhibitor and specifically induces apoptosis of senescent cells [<xref ref-type="bibr" rid="c29">29</xref>, <xref ref-type="bibr" rid="c30">30</xref>]. Micro-CT analysis demonstrated that ABT-263 could also relieve periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (<xref rid="fig5" ref-type="fig">Fig. 5F</xref>). Together, these results demonstrate that the elimination of senescent cells using senolytic drugs is effective in alleviating musculoskeletal pathologies in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> animals, confirming that osteogenic cell senescence is responsible for musculoskeletal abnormalities in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice.</p>
</sec>
<sec id="s2f">
<title>CHMP5 is essential for endolysosomal functions and maintaining VPS4A protein in skeletal progenitors</title>
<p>Next, we wondered whether <italic>Chmp5</italic> deficiency in skeletal progenitors affects the endocytic pathway. Notably, approximately 45% of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors contained enlarged GFP<sup>+</sup> vesicles, which were rarely found in <italic>wild-type Ctsk<sup>+</sup></italic> periskeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6A</xref>), suggesting a possible issue of the endocytic pathway in <italic>Chmp5</italic>-deleted skeletal progenitors. Next, we used molecular markers for different components and the function of the endocytic pathway to elucidate the influence of <italic>Chmp5</italic> deficiency on the endolysosomal system in skeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6B</xref>).</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 6.</label>
<caption><title>CHMP5 is essential for endolysosomal functions and maintaining VPS4A protein in skeletal progenitors.</title><p>(<bold>A</bold>) Representative confocal images demonstrating abnormally enlarged vesicles in cultured <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>wild-type</italic> periskeletal progenitors. Abnormal cells identified by containing enlarged GFP<sup>+</sup> vesicles. <italic>n</italic> = 200 cells from 3 mice per group. (<bold>B</bold>) Schematic showing molecular markers utilized to analyze the endocytic pathway. (<bold>C</bold>) Representative confocal images showing LAMP1 immunostaining in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 20 cells per group. (<bold>D</bold>) Quantification of LAMP1<sup>+</sup> vesicles in ATDC5 cells with or without <italic>Chmp5</italic> depletion. <italic>n</italic> = 93, 66 cells, respectively. (<bold>E</bold>) Representative confocal images showing RAB7 immunostaining in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 15 cells per genotype. (<bold>F</bold>) Quantification of RAB7<sup>+</sup> vesicles in ATDC5 cells with or without <italic>Chmp5</italic> depletion. <italic>n</italic> = 94, 92 cells, respectively. (<bold>G</bold>) Transmission electron microscopy showing the accumulation of multivesicular body-like structures (arrows) and lysosome-like structures (arrowheads) in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 30 cells per group. (<bold>H</bold>) Confocal live cell images demonstrating delayed degradation of the EGF conjugate in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 10 cells each group per time point. (<bold>I</bold>) Volcano plot of proteomic analysis showing differentially expressed proteins in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 3 with cells from 3 different animals. (<bold>J</bold>) Western blot verifying the decrease in VPS4A protein in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. The numbers above lanes indicating the intensity of the VPS4A band relative to that of <italic>wild-type</italic> cells after normalization by β-Actin. Results repeated 3 times with cells from 3 different mice each group. All data are mean ± s.d.; Mann-Whitney test for the comparison of the vesicle number and two-tailed unpaired Student’s <italic>t</italic>-test for the comparison of the vesicle size in (<bold>D</bold>) and (<bold>F</bold>). Scale bars, 10 μm except (<bold>G</bold>) as indicated.</p></caption>
<graphic xlink:href="233874v4_fig6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>The LysoTracker Red DND-99 trace and the immunostaining of lysosome-associated membrane protein 1 (LAMP1) showed positive staining in many of the enlarged vesicles in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6C</xref> and <xref rid="figs6" ref-type="fig">Fig. S6A, B</xref>). The quantification of the number and average size of LAMP1 stained vesicles were further performed in ATDC5 cells with or without <italic>Chmp5</italic> deletion (<xref rid="fig6" ref-type="fig">Fig. 6D</xref>). Next, the number and size of the vesicles stained for the late endosome marker RAB7 also increased markedly in <italic>Chmp5</italic>-deficient relative to <italic>wild-type</italic> skeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6E, F</xref>). Meanwhile, many of these accumulated vesicles were double positive for LAMP1 and RAB7 (<xref rid="figs6" ref-type="fig">Fig. S6C, D</xref>), suggesting that they are terminal compartments in the endocytic pathway. Accordingly, the transmission electron microscopy demonstrated a significant accumulation of MVB-like and lysosome-like structures with different electronic density in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6G</xref>).</p>
<p>To examine the function of the endocytic pathway, we used a pH-sensitive fluorescent EGF conjugate and traced the degradation of the internalized EGF receptor in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. <italic>Chmp5</italic> deficiency significantly delayed the degradation of the EGF conjugate in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6H</xref>), indicating altered function of the endocytic pathway. It should be noted that the early endosomes of EEA1<sup>+</sup> also increased slightly in approximately 10% of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors, while the recycling endosomes of RAB11<sup>+</sup> and the TGN38<sup>+</sup> trans-Golgi network were relatively normal (<xref rid="figs6" ref-type="fig">Fig. S6E</xref>). These results demonstrate that CHMP5 deficiency in skeletal progenitors causes the accumulation of late endosomes and lysosomes and disrupts the function of the endolysosomal pathway.</p>
<p>To dissect the molecular mechanism of CHMP5 that regulates the endolysosomal pathway, we performed a proteomic analysis in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors. Bioinformatic analyses of proteomic data showed that VPS4A is one of the most significant decreased proteins in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors (<xref rid="fig6" ref-type="fig">Fig. 6I</xref>). The decrease in the VPS4A protein in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors was verified by Western blot analysis (<xref rid="fig6" ref-type="fig">Fig. 6J</xref>), while the <italic>Vps4a</italic> mRNA did not show a significant change in the RNA-seq analysis (<xref rid="figs6" ref-type="fig">Fig. S6F</xref>). On the other hand, when CHMP5 was overexpressed by transfection of a CHMP5 vector into HEK-293T cells, the level of VPS4A protein increased significantly and <italic>VPS4A</italic> mRNA was not significantly affected (<xref rid="figs6" ref-type="fig">Fig. S6G, H</xref>). These results indicate that CHMP5 is essential in maintaining the VPS4A protein. Since VPS4A is a critical ATPase mediating the function of the ESCRT-III protein complex, the reduction of VPS4A protein could be responsible for endolysosomal dysfunction in <italic>Chmp5</italic>-deleted skeletal progenitors.</p>
</sec>
<sec id="s2g">
<title>Mitochondrial dysfunction is responsible for cell senescence in <italic>Chmp5</italic>-deleted skeletal progenitors</title>
<p>A remaining question is how <italic>Chmp5</italic> deficiency and endolysosomal dysfunction cause skeletal cell senescence. Impairment of lysosomal functions could hinder the degradation of damaged mitochondria, resulting in the accumulation of reactive oxygen species (ROS) in mitochondria [<xref ref-type="bibr" rid="c31">31</xref>, <xref ref-type="bibr" rid="c32">32</xref>]. Indeed, the GSEA of RNA-seq data showed significant enrichment of genes associated with the molecular pathway of oxidative stress-induced cell senescence in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors (<xref rid="fig7" ref-type="fig">Fig. 7A</xref>). Accordingly, the level of mitochondrial ROS and the abundance of mitochondria increased markedly in <italic>Chmp5</italic>-deficient compared to <italic>wild-type</italic> skeletal progenitors, as shown by CellRox, tetramethylrhodamine methyl ester (TMRE), and MitoTracker fluorescence stain, and expression levels of mitochondrial inner membrane proteins NDUF88, SDHB, and ATP5A (<xref rid="fig7" ref-type="fig">Fig. 7B</xref> to <xref ref-type="fig" rid="fig7">D</xref> and <xref rid="figs7" ref-type="fig">Fig. S7A, B</xref>).</p>
<fig id="fig7" position="float" orientation="portrait" fig-type="figure">
<label>Fig. 7.</label>
<caption><title>Mitochondrial dysfunction is responsible for cell senescence in <italic>Chmp5</italic>-deleted skeletal progenitors.</title><p>(<bold>A</bold>) GSEA of RNA--seq data reporting positive enrichment of genes associated with the molecular pathway of oxidative stress-induced senescence in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. (<bold>B</bold>) Confocal fluorescence images showing intracellular ROS (CellROX Deep Red) and mitochondria (TMRE) in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. Images are representative of 30 cells per group. Scale bars, 15 μm. The graph on the right shows the quantification of the fluorescence intensity of CellROX Deep Red. <italic>n</italic> = 10 each group, results repeated twice. (<bold>C</bold>) Quantification of TMRE fluorescence intensity in <italic>Chmp5</italic>-sufficient and <italic>Chmp5</italic>-deficient ATDC5 cells. <italic>n</italic> = 12 for each group, repeated 3 times. (<bold>D</bold>) Western blotting determining the expression of mitochondrial OXPHOS proteins NDUF88, SDHB, MT-CO1, UQCRC2, and ATF5A in <italic>Chmp5</italic>-deficient compared to <italic>Chmp5</italic>-sufficient ATDC5 cells. Experiment repeated twice. (<bold>E</bold>) Cell number counting to determine cell proliferation in galactose medium. <italic>n</italic> = 6 replicates per group, repeated three times. (<bold>F</bold>) Seahorse mitochondrial stress test showing mitochondrial respiratory capacity and extracellular acidification rate in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>wild-type</italic> periskeletal progenitors. Data pooled from cells of 3 mice, 8 replicates for each sample. (<bold>G</bold>) Cell number counting and AlamarBlue assay determining cell proliferation in ATDC5 cells with or without <italic>Chmp5</italic> depletion after treatment with the antioxidant <italic>N</italic>-Acetyl cysteine. <italic>n</italic> = 3 or 12 each group for cell number counting or AlamarBlue assay, respectively; results repeated 3 times. (<bold>H</bold>) Schematic showing the function of CHMP5 in maintaining VPS4A protein and endolysosomal homeostasis and restricting cell senescence and osteogenesis in skeletal progenitors. All data are mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test, except the Mann-Whitney test in panel (<bold>E</bold>).</p></caption>
<graphic xlink:href="233874v4_fig7.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>Mitochondrial functions were also compromised in <italic>Chmp5</italic>-deficient skeletal progenitors as shown by decreased mitochondrial respiratory capacity, increased extracellular acidification rate, and reduced tolerance to galactose (<xref rid="fig7" ref-type="fig">Fig. 7E</xref> and <xref rid="fig7" ref-type="fig">F</xref>). Furthermore, mitochondrial dysfunction and DNA damage response usually form a feedback loop to drive senescent cell phenotypes [<xref ref-type="bibr" rid="c33">33</xref>–<xref ref-type="bibr" rid="c35">35</xref>]. The GSEA of the RNA-seq data also showed enrichment of genes associated with DNA damage-induced cell senescence in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> skeletal progenitors (<xref rid="figs7" ref-type="fig">Fig. S7C</xref>). Upregulation of two critical DNA damage-responsive genes <italic>H2afx</italic> and <italic>Trp53</italic> was verified by qPCR in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> skeletal progenitors (<xref rid="figs7" ref-type="fig">Fig. S7D</xref>). Importantly, N-Acetylcysteine (NAC) antioxidant treatment could reverse the reduced activity of cell proliferation in <italic>Chmp5</italic>-deficient skeletal progenitors (<xref rid="fig7" ref-type="fig">Fig. 7G</xref>). Therefore, the accumulation of dysfunctional mitochondria and mitochondrial ROS is responsible for cell senescence in <italic>Chmp5</italic>-deficient skeletal progenitors.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>In this study, our results reveal the role and mechanism of CHMP5 in the regulation of cell senescence and bone formation in osteogenic cells. In normal skeletal progenitor cells, CHMP5 is essential in maintaining the VPS4A protein, a critical AAA ATPase for the functions of the ESCRT-III protein complex. The deficiency of CHMP5 decreases the VSP4A protein and causes the accumulation of dysfunctional late endosomes (MVB), lysosomes, and mitochondria, which induce skeletal cell senescence and result in increased bone formation through a combination of cell-autonomous and paracrine mechanisms (<xref rid="fig7" ref-type="fig">Fig. 7H</xref>). Strikingly, elimination of senescent cells using senolytic drugs is effective in mitigating abnormal bone formation.</p>
<p>The role of CHMP5 in cell senescence has not been reported. As the mechanisms and functions of cell senescence could be highly heterogeneous depending on inducers, tissue and cell contexts, and other factors such as “time” [<xref ref-type="bibr" rid="c36">36</xref>–<xref ref-type="bibr" rid="c38">38</xref>], there is currently no universal molecular marker to define all types of cell senescence. In this study, <italic>Chmp5</italic>-deficient skeletal progenitors show multiple canonical features of senescent cells, including increased p16 and p21 proteins and γH2Ax<sup>+</sup> cells, cell cycle arrest, elevated secretory phenotype, accumulation and dysfunction of lysosomes and mitochondria. Also, <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice show dramatic aging-related phenotypes, including hair loss, joint stiffness/contracture, decreased bone strength, or gradual loss of muscle mass and functions. Importantly, senolytic drugs markedly improve musculoskeletal abnormalities and increase animal motility in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice. These results reveal the role of CHMP5 in controlling the senescence of skeletal cells.</p>
<p>CHMP5 has been reported to regulate VPS4 activity, which catalyzes the disassembly of the ESCRT-III protein complex from late endosomes/MVBs, by binding directly to the VPS4 protein or other protein partners such as LIP5 and Brox [<xref ref-type="bibr" rid="c39">39</xref>, <xref ref-type="bibr" rid="c40">40</xref>]. However, it remains unknown how CHMP5 regulates VPS4 activity. Our results in this study show that CHMP5 is necessary to maintain the VPS4A protein but does not affect the level of VPS4A mRNA, suggesting that CHMP5 regulates VPS4 activity by maintaining the level of the VPS4A protein. However, the mechanism of CHMP5 in the regulation of the VPS4A protein has not yet been studied. Since CHMP5 can recruit the deubiquitinating enzyme USP15 to stabilize IκBα in osteoclasts by suppressing ubiquitination-mediated proteasomal degradation [<xref ref-type="bibr" rid="c8">8</xref>], it is also possible that CHMP5 stabilizes the VPS4A protein by recruiting deubiquitinating enzymes and regulating the ubiquitination of VPS4A, which needs to be clarified in future studies. Notably, mutations in the <italic>VPS4A</italic> gene in humans can cause multisystemic diseases, including musculoskeletal abnormalities [<xref ref-type="bibr" rid="c41">41</xref>] (OMIM: 619273), suggesting that normal expression and function of VPS4A are important for musculoskeletal physiology. The roles of VPS4A in regulating musculoskeletal biology and cell senescence should be further explored in future studies.</p>
<p>The upstream signaling that regulates CHMP5 expression in osteogenic cells is unclear. Previous studies showed that muramyl-dipeptide and lipopolysaccharide upregulate CHMP5 expression in human monocytes [<xref ref-type="bibr" rid="c42">42</xref>, <xref ref-type="bibr" rid="c43">43</xref>]. Whether the mechanism also occurs in osteogenic cells remains to be determined, especially since many molecular and cellular mechanisms are cell lineage/type dependent. In addition, an earlier study showed that <italic>Rank</italic> haploinsufficiency in <italic>Chmp5<sup>Ctsk</sup></italic> mice (<italic>Chmp5<sup>Ctsk</sup>;Rank<sup>+/−</sup></italic>) could greatly reverse skeletal abnormalities in these animals, including periskeletal overgrowth [<xref ref-type="bibr" rid="c8">8</xref>]. Therefore, RANK receptor signaling may function upstream of CHMP5. However, whether RANK is expressed in osteogenic cells needs additional studies to clarify. Otherwise, other epigenetic, transcriptional, translational, or post-translational mechanisms may also play a role in the regulation of CHMP5 expression in osteogenic lineage cells in physiological and pathological contexts.</p>
<p>A previous study using the <italic>Chmp5<sup>Ctsk</sup></italic> mouse model defined a function of CHMP5 in the regulation of osteoclast differentiation by tuning NF-κB signaling [<xref ref-type="bibr" rid="c8">8</xref>]. While the evidence on the role of CHMP5 in osteoclastogenesis is robust in that study, our results in the current study provide compelling evidence on the role of CHMP5 in bone formation in osteogenic cells. Furthermore, the function of CHMP5 in restricting bone formation was confirmed in the <italic>Chmp5<sup>Dmp1</sup></italic> mouse model and in the MC3T3-E1 cell model (<xref rid="fig1" ref-type="fig">Figs. 1</xref> and <xref rid="fig2" ref-type="fig">2</xref>). Therefore, it is probable that both osteoclast and osteoblast lineage cells contribute to bone deformation in <italic>Chmp5<sup>Ctsk</sup></italic> mice. However, the previous study by Greenblatt et al. did not find endolysosomal abnormalities in osteoclasts after <italic>Chmp5</italic> deletion, and in that study cell senescence and mitochondrial functions were not measured. Also, a previous study by Adoro et al. did not detect endolysosomal abnormalities in <italic>Chmp5</italic>-deficient developmental T cells [<xref ref-type="bibr" rid="c9">9</xref>]. Since both osteoclasts and T cells are of hematopoietic origin, and meanwhile osteogenic cells and MEFs, which show endolysosomal abnormalities after CHMP5 deficiency, are of mesenchymal origin, it turns out that the function of CHMP5 in regulating the endolysosomal pathway could be cell lineage-specific, which remains clarified in future studies.</p>
<p>Furthermore, it is unclear whether the effect of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice involves targeting osteoclasts other than osteogenic cells, as osteoclast senescence has not yet been evaluated. However, the efficacy of Q + D in targeting osteogenic cells, which is the focus of the current study, was confirmed in <italic>Chmp5<sup>Dmp1</sup></italic> mice (<xref rid="fig5" ref-type="fig">Fig. 5C-E</xref>). Additionally, Q + D caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors in <italic>ex vivo</italic> culture (<xref rid="fig5" ref-type="fig">Fig. 5A</xref>), demonstrating the effectiveness of Q + D in targeting osteogenic cells in the <italic>Chmp5<sup>Ctsk</sup></italic> model. Furthermore, an alternative senolytic drug ABT-263 could also ameliorate periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (<xref rid="fig5" ref-type="fig">Fig. 5F</xref>). Together, these results confirm that osteogenic cell senescence is responsible for the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice and senolytic treatments are effective in alleviating these skeletal disorders.</p>
<p>Notably, aging is associated with decreased osteogenic capacity in marrow stromal cells, which is related to conditions with low bone mass, such as osteoporosis. Rather, aging is also accompanied by increased ossification or mineralization in musculoskeletal soft tissues, such as tendons and ligaments [<xref ref-type="bibr" rid="c44">44</xref>]. In particular, the abnormal periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was predominantly mapped to the insertion sites of tendons and ligaments on the bone (<xref rid="fig1" ref-type="fig">Fig. 1A</xref> and <xref rid="fig1" ref-type="fig">E</xref>), which is consistent with changes during aging and suggests that mechanical stress at these sites could contribute to the aberrant bone growth. These results suggest that skeletal stem/progenitor cells at different sites of musculoskeletal tissues could demonstrate different, even opposite outcomes in osteogenesis, due to cell senescence.</p>
<p>In addition, there was also a mild increase in apoptotic cells in the population of <italic>Chmp5</italic>-deficient skeletal progenitors (approximately 5%). Since anti-apoptotic treatment with the pan-caspase inhibitor Q-VD-Oph could not reverse the decrease in cell number in <italic>Chmp5</italic>-deficient skeletal progenitors, cell apoptosis may not be the main cause of the decrease in cell proliferation rate in these progenitors. It should be noted that although senescent cells are generally resistant to apoptosis, the gradual accumulation of dysfunctional lysosomes and mitochondria in <italic>Chmp5</italic>-deficient skeletal progenitors could result in overload of toxic macromolecules and metabolites, which could activate the apoptotic pathway to eliminate severely damaged cells. Otherwise, CHMP5 may regulate cell senescence and apoptosis through different mechanisms.</p>
<p>In summary, we have revealed the role of CHMP5 in the regulation of cell senescence and bone formation in osteogenic cells. This study also confirms the essential function of CHMP5 in the endolysosomal pathway that involves the regulation of the VPS4A protein. Additionally, mitochondrial functions are impaired with CHMP5 deletion, which is responsible for cell senescence. Future studies should explore the mechanism of CHMP5 in the regulation of mitochondrial functions. Since <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice recapitulate many cellular and phenotypic features of musculoskeletal lesions in lysosomal storage disease, these animals could be used as preclinical models to investigate the mechanism and test therapeutic drugs for these intractable disorders.</p>
</sec>
<sec id="s6">
<title>Methods</title>
<sec id="s6a">
<title>Mice</title>
<p>In this study, two <italic>Chmp5</italic>-flox mouse strains were used, and similar phenotypes were observed. The <italic>Chmp5<sup>tm2.1Gho</sup></italic> strain was previously described [<xref ref-type="bibr" rid="c8">8</xref>]. The alternative <italic>Chmp5</italic>-flox strain was established by CRISPR/Cas9-mediated genome engineering. Similarly to the <italic>Chmp5<sup>tm2.1Gho</sup></italic> strain, exons 4 and 5 were selected as the conditional knockout region in the newly created strain and deletion of this region results in frameshift of the <italic>Chmp5</italic> gene. To engineer the target vector, homologous arms, and the conditional knockout region with 5’ and 3’ loxP sites were generated by PCR using the BAC clone. Cas9, gRNA, and targeting vectors were co-injected into fertilized eggs for gene-edited mouse production and pups were genotyped by PCR followed by sequencing analysis. Mice bearing the targeted allele were backcrossed with C57BL/6J mice up to F8 generation.</p>
<p>Ctsk<sup>tm1(cre)Ska</sup> (Ctsk<sup>Cre</sup>), B6N.FVB-Tg(Dmp1-cre)1Jqfe/BwdJ (Dmp1-Cre), B6.Cg-Tg(Prrx1-cre)1Cjt/J (Prrx1<sup>Cre</sup>), B6;SJL-Tg(Col2a1-cre)1Bhr/J (Col2-Cre), and B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J (Osx1-GFP::Cre) mice have previously been reported [<xref ref-type="bibr" rid="c8">8</xref>, <xref ref-type="bibr" rid="c17">17</xref>, <xref ref-type="bibr" rid="c45">45</xref>–<xref ref-type="bibr" rid="c47">47</xref>]. While the Ctsk-Cre strain is a knockin mouse line, other strains (Dmp1-Cre, Prrx1-Cre, Col2-Cre, and Osx-Cre) are transgenic lines. The Gt(ROSA)26Sor<sup>tm4(ACTB-tdTomato,-EGFP)Luo</sup> (Rosa26<sup>mTmG</sup>) mice were purchased from Jackson Laboratories. To generate experimental animals, <italic>Chmp5<sup>fl/fl</sup></italic> mice were crossed with <italic>Chmp5<sup>Ctks/+</sup></italic> and <italic>Chmp5<sup>Dmp1/+</sup></italic> mice, respectively. To generate reporter mouse lines, <italic>Chmp5<sup>Ctks/+</sup></italic> mice were mated with <italic>Chmp5<sup>fl/fl</sup></italic>;<italic>Rosa26<sup>mTmG</sup></italic> mice, and Ctsk<sup>Cre</sup> mice were crossed with Rosa26<sup>mTmG</sup> animals.</p>
<p>All mice were kept in C57BL/6J background and housed in the standard animal facility on a 12-hour light/dark cycle with ad libitum access to water and standard chow. In most situations, the littermates were compared otherwise as indicated. All animals were used in accordance with the Guide for Care and Use of Laboratory Animals (NIH, United States) and were handled according to protocols approved by IACUC at the University of Massachusetts Medical School (Worcester, United States) and Capital Medical University (Beijing, China). The biological and technical replicates (<italic>n</italic> numbers) for each animal experiment are reported in the figure legends. In this study, both sexes of mice were used and, unless otherwise stated, no gender differences were observed in the reported phenotypes.</p>
</sec>
<sec id="s6b">
<title>Micro-CT and radiography</title>
<p>Micro-CT analyses were performed using the Scanco μCT-35 or μCT-40 scanner (Scanco Medical). Images were processed using the Inveon Research Workplace (Siemens Medical Solutions). X-ray images were acquired using the X-Ray MX-20 Specimen (Faxitron) following the default programme.</p>
</sec>
<sec id="s6c">
<title>Histology, immunohistochemistry, and immunofluorescence</title>
<p>All samples were fixed in 10% neutral formalin or 4% paraformaldehyde overnight for premature samples or 2 days for mature skeletal samples. Samples were decalcified with 14% EDTA and serial sections were cut for all samples. At least five slides were selected at a certain interval (80-100 μm) from each sample for histological evaluation. Fate-mapping images were acquired using a Leica TCS SP5 II laser scanning confocal microscope.</p>
<p>Immunofluorescence for γH2AX was performed using a Phospho-Histone H2A.X (Ser139) antibody (clone 20E3, CST). Immunohistochemistry for Ki-67 was performed using the VECTASTAIN® Elite® ABC HRP Kit (Peroxidase, Rabbit IgG; Vector Laboratories). Cells for immunofluorescence were cultured in 35 mm MatTek glass bottom dishes (No. 1.5 coverslip, MatTek Corporation). Briefly, tissues or cells were fixed in 4% PFA for 15 min, blocked in 1% BSA for 30 min, and incubated with primary antibodies for 2 hrs and then fluorescence conjugated secondary antibodies for 1 hr. Images were acquired using the Leica TCS SP5 II laser scanning confocal microscope. The quantification of intracellular vesicles was performed using FIJI software following the particle analysis procedure (<ext-link ext-link-type="uri" xlink:href="https://imagej.net/imagej-wiki-static/Particle_Analysis">https://imagej.net/imagej-wiki-static/Particle_Analysis</ext-link>, NIH).</p>
</sec>
<sec id="s6d">
<title>Bone mechanical test</title>
<p>The femurs of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>fl/fl</sup></italic> mice at 6-7 weeks of age were subjected to mechanical testing using the DMA Q800 mechanical test system with the 3-point bending mode following the manufacturer’s procedure (TA Instruments, USA). The femurs were placed in a direction of the anterior surface downward and the posterior aspect of the femoral condyles facing upward. The span length (L) was 10 mm and the load was applied in the middle of the bone. Five mice per group were used and bone stiffness and ultimate stress (fracture stress) from male mice were reported. Similar changes were observed in both sexes.</p>
</sec>
<sec id="s6e">
<title>Tests of skeletal muscle functions</title>
<p>The four-limb hanging test was performed using the top grid of a mouse cage [<xref ref-type="bibr" rid="c48">48</xref>]. The grid was set at a height of about 35 cm, and the measurement was repeated for 3-5 times for each mouse at a rest interval of about 3-5 min. The maximum hang time was recorded for each animal. Both male and female animals were included in this experiment, and there was no significant sex difference regarding the four-limb hanging time.</p>
<p>The forelimb grip strength test was carried out using an electronic scale as described with slight modification [<xref ref-type="bibr" rid="c48">48</xref>, <xref ref-type="bibr" rid="c49">49</xref>]. A mouse was allowed to grasp the gauze attached on the scale. The scale was reset to 0 g after stabilization and a researcher slowly pulled the mouse’s tail backward. Five consecutive measurements were performed for each mouse and the peak pull force in grams was recorded. A significant sex difference was observed in the forelimb grip strength. Both male and female mice were included in this study and the same trend of changes was found in both genders.</p>
</sec>
<sec id="s6f">
<title>Skeletal progenitor cell culture and sorting</title>
<p>The periskeletal progenitors were isolated from the hindlimbs of <italic>Ctsk-Cre;Rosa26<sup>mTmG/+</sup></italic>, <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>mTmG/+</sup></italic>, and <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice (<italic>n</italic> = 10 animals per genotype) at 2 weeks of age according to the previously established method [<xref ref-type="bibr" rid="c23">23</xref>]. Briefly, the periskeletal tissues were dissected, minced into small pieces, and digested with 1 mg/ml collagenase type I (Worthington), 1 mg/ml collagenase type II (Worthington) and 1.5 mg/ml dispase (Roche) for 30 min at 37°C. Cells were cultured in skeletal stem cell medium (Joint Therapeutics, Beijing, China) for one week, stained with anti-CD31 and anti-CD45 antibodies, and sorted using a FACSAria II cell sorter (BD Biosciences) for further analyses.</p>
<p>In all experiments, <italic>Chmp5<sup>Ctsk</sup></italic> and control cells from littermate mice were cultured, sorted, and re-seeded in parallel for subsequent analyses. The coculture experiment was carried out by directly mixing 90% <italic>wild-type</italic> skeletal progenitors with 10% <italic>Chmp5<sup>Ctsk</sup></italic> or control periskeletal progenitors to simulate the in vivo context of cell-cell contact in periskeletal overgrowth. The cocultures were induced in osteogenic differentiation medium for 4 weeks. The biological and technical replicates (<italic>n</italic>-numbers) for each cellular experiment are reported in the figure legends.</p>
</sec>
<sec id="s6g">
<title>CRISPR/CAS9 lentiviral infection</title>
<p>Pairs of CRISPR guide RNA oligos (mouse <italic>Chmp5</italic> single guide RNAs [sgRNAs] targeting GGCTCCGCCACCTAGCTTGA and GTTTCGCTTTTCCGAAGAAT on exon 1 respectively) were annealed and cloned into the BsmBI sites of the lentiCRISPR V2-puro vector (plasmid 52961, Addgene). CRISPR lentiviral plasmids and lentiviral packaging plasmids (pMDLg/pRRE, pRSV-Rev, and pMD2.G; Addgene) were transfected into HEK 293T cells. The supernatants were harvested and filtered through a 0.45-μm filter 2.5 days after transfection. MC3T3-E1 and ATDC5 cells were infected with CRISPR lentivirus and selected with puromycin (4.5 μg/ml, Clontech) for 7 days. The depletion of <italic>Chmp5</italic> was confirmed by Western blotting.</p>
</sec>
<sec id="s6h">
<title><italic>In vitro</italic> osteogenesis</title>
<p>For osteogenic differentiation, 1.0 x 10<sup>5</sup> cells were seeded in each well of 24-well plates and cultured overnight. Cells were changed into osteogenic media (Joint Therapeutics) the next day and induced for the indicated times. Osteogenesis was determined by alizarin red and von Kossa staining and by examining the activity of alkaline phosphatase.</p>
</sec>
<sec id="s6i">
<title>Cell cycle, proliferation, and apoptosis analyses</title>
<p>The cell number was counted with a Countess II FL Automated Cell Counter (ThermoFisher Scientific, USA) at indicated time intervals. The AlamarBlue cell viability assay was performed as previously described [<xref ref-type="bibr" rid="c23">23</xref>]. The cell cycle was determined using the APC-BrdU Flow Kit (BD Biosciences). In vitro apoptosis analysis was carried out with Annexin V-PI staining and in situ cell apoptosis was determined with TUNEL staining (Abcam).</p>
</sec>
<sec id="s6j">
<title>RNA-seq, data analysis, and functional annotation</title>
<p>The sorted <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors were subjected to RNA-seq For library preparation, 100 ng of total RNA from each sample was subjected to rRNA depletion with the NEBNext rRNA Depletion Kit (New England Biolabs) according to the manufacturer’s manual. Subsequently, the rRNA-depleted RNA was used to build the RNA-seq library with the NEBNext Ultra II Directional RNA Library Prep Kit (New England Biolabs) according to the manufacturer’s manual. The index of each RNA-seq library was introduced using NEBNext Multiplex Oligos for Illumina (New England Biolabs). Each RNA-seq library was analyzed by the fragment analyzer (Advanced Analytical Technologies) and quantified by the KAPA Library Quantification Kit (KAPA Biosystems) according to the manufacturer’s manual. An equal amount of each RNA-seq library was mixed for sequencing in one lane of Illumnia HiSeq3000 in paired-end 150 base mode (Illumina).</p>
<p>The raw Illumina pair-end reads were first aligned with ribosomal RNA (GenBank ID BK000964.1) with Bowtie2 v2.2.6 [<xref ref-type="bibr" rid="c50">50</xref>]. Reads that failed to map to ribosomal RNA were aligned with the mouse reference genome mm10 with STAR v2.5.3 [<xref ref-type="bibr" rid="c51">51</xref>]. Differential analysis was performed with Cuffdiff v2.2.1 [<xref ref-type="bibr" rid="c52">52</xref>]. The raw data were analyzed by two independent statisticians and similar results were obtained.</p>
<p>Pathway analyses were performed for differentially expressed genes using the Reactome online analysis tool [<xref ref-type="bibr" rid="c53">53</xref>] and the Ingenuity Pathway Analysis software (Qiagen). Gene ontology term over-representation analysis was run using PANTHER (version 14.1) with all genes expressed in a tissue or cell type as background and the differentially expressed gene list as input. The P-values of Fisher’s exact tests were corrected by controlling the false discovery rate (FDR). Gene set enrichment analyses were performed using GSEA or ConsensusPathDB. For GSEA-based analysis, gene sets of interests were downloaded from the MsigDB, while all built-in gene sets were used for ConsensusPathDB-based analysis.</p>
</sec>
<sec id="s6k">
<title>Nano LC-MS/MS for secretomic and proteomic analyses</title>
<p>Label-free relative protein quantification analyses were performed to identify differentially expressed proteins in the supernatant or cell lysis of <italic>Chmp5<sup>Ctsk</sup></italic> versus control periskeletal progenitors (<italic>n</italic> =3 animals per group). For cell supernatants, the same amounts of samples went through 3 kD ultrafiltration tubes and then were processed for reduction and alkylation. Subsequently, the samples were digested in trypsin overnight and the peptides were desalted prior to mass spectrometry analysis. For cell lysis, samples were precipitated using acetone after reduction and alkylation. The samples were then subjected to digestion, desalination, and mass spectrometry analysis.</p>
<p>Quantitative data were collected on an Orbitrap Eclipse™ Tribrid<sup>TM</sup> mass spectrometer (ThermoFisher Scientific) coupled to a nanoLC system (EASY-nLC™ 1200, ThermoFisher Scientific). All peptide mixtures were analyzed using the same chromatographic conditions: 5 μl of each sample were fractionated in a 150 μm×15 cm in-house made column packed with Acclaim PepMap RPLC C18 (1.9 μm, 100 Å, Dr. Maisch GmbH, Germany) working at a flow rate of 600 nl/min, using a linear gradient of eluent B (20% 0.1% formic acid in water + 80% acetonitrile) in A (0.1% formic acid in MilliQ water) from 4% to 10% for 5 min, 10% to 22% for 80 min, 22% to 40% for 25 min, 40% to 95% for 5 min, and 95% to 95% for 5 min. MS/MS analyses were performed using Data-Dependent Acquisition (DDA) mode: one MS scan (mass range from 350 to 1500 m/z) was followed by MS/MS scans up to the top 20 most intense peptide ions from the preview scan in the Orbitrap, applying a dynamic exclusion window of 120 seconds.</p>
<p>The raw MS files were analyzed and searched against the Mus_musculus_reviewed protein database using MaxQuant (1.6.2.10). The parameters were set as follows: the protein modifications were carbamidomethylation (C) (fixed), oxidation (M) (variable), acetyl (Protein N-term) (variable); the enzyme specificity was set to trypsin; the maximum missed cleavages were set at 2; the precursor ion mass tolerance was set at 20 ppm; and the MS/MS tolerance was 20 ppm. Only highly confident identified peptides were chosen for downstream protein identification analysis.</p>
</sec>
<sec id="s6l">
<title>Western blotting</title>
<p>Western blot was performed using 4–20% Mini-PROTEAN® TGX™ precast protein gels (Bio-Rad). The following antibodies: anti-CHMP5 polyclonal antibody [<xref ref-type="bibr" rid="c6">6</xref>], anti-COL1A1 monoclonal antibody (clone E8F4L, Cell Signaling Technology, CST), anti- AGLN polyclonal antibody (cat#: AB14106, Abcam), anti-p16 INK4A monoclonal antibody (clone E5F3Y, CST), anti-p21 Waf1/Cip1 monoclonal antibody (clone E2R7A, CST), anti-VPS4A monoclonal antibody (clone A-11, Santa Cruz Technology), total OXPHOS antibody cocktail (Abcam), anti-GAPDH monoclonal antibody (clone 14C10, CST), and anti-β-Actin monoclonal antibody (clone D6A8, CST), were used.</p>
</sec>
<sec id="s6m">
<title>Quantitative PCR</title>
<p>Total RNA was isolated from cells using Trizol reagent (Qiagen). RNA samples were treated with the TURBO DNA-free<sup>TM</sup> Kit (Thermo Fisher) and equal amounts (1–2 μg) were used for reverse transcriptase reaction using an iScript™ Reverse Transcription Supermix (Bio-Rad). Quantitative PCR was run using the SYBR® Green Master Mix on a CFX Connect™ Real-Time PCR Detection System (Bio-Rad). Gene expression levels were analyzed relative to the housekeeping gene <italic>Gapdh</italic> and presented by 2<sup>−△Ct</sup> [<xref ref-type="bibr" rid="c54">54</xref>]. The primer sequences were used for qPCR are as following: <italic>Chmp5,</italic> forward, 5’-ATGAGAGAGGGTCCTGCTAAG-3’, reverse, 5’-CCGTGGTCTTGGTGTCCTTTA-3’; <italic>H2afx</italic>, forward, 5’-GTGGTCTCTCAGCGTTGTTC-3’, reverse, 5’-CGGCC TACAGGGAACTGAA-3’; <italic>Tp53</italic>, forward, 5’-GTCACAGCACATGACGGAGG-3’, reverse, 5’-TCTTCCAGATGCTCGGGATAC-3’; <italic>Gapdh</italic>, forward 5′-TGCCAGCCTCGTCCCG TAGAC-3′, reverse 5′-CCTCACCCCATTTGATGTTAG-3′; <italic>VPS4A</italic>, forward 5′-AGAACCAGAGTGAGGGCAAGGG-3′, reverse 5′-GCACCCATCAGCTGTTCTTGCA-3′; <italic>CHMP5</italic>, forward 5′-CCAGCCTGACTGACTGCATTGG-3′, reverse 5′-TCGCAAGGCTTTCTGCTTGACC-3′; <italic>GAPDH</italic>, forward 5′-GGAGTCCACTGGCGTCTTCAC-3′, reverse 5′-GAGGCATTGCTGATGATCTTGAGG-3′.</p>
</sec>
<sec id="s6n">
<title>Extracellular vesicle tracking</title>
<p>The concentration and size distribution of extracellular vesicles were analyzed using the NanoSight NS300 following the manufacturer’s protocol (Malvern Instruments). Briefly, cells were seeded in 24-well plates at the density of 1 x 10<sup>5</sup> cells per well and cultured overnight. The next morning, cells were changed to serum-free medium and incubated for 9 hrs. The medium was collected and subjected to sequential centrifugation at 300 g for 10 min, 2000 g for 20 min, and 10000 g for 30 min. The resulting supernatant was manually injected into the instrument and run in the “standard measurement” module with five captures per sample and the data were processed with a detection threshold of 2.</p>
</sec>
<sec id="s6o">
<title>Live-cell imaging for cell endocytosis</title>
<p>The <italic>wild-type</italic> and <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors were incubated on ice for 10 min before adding fresh medium with 2 ug/ml pHrodo™ red EGF conjugate (ThermoFisher). Cells were incubated at 37 °C for 30 min and subsequently washed and changed to fresh medium. Live-cell images were obtained at 1, 12, and 24 hrs using the Leica TCS SP5 II laser scanning confocal microscope.</p>
</sec>
<sec id="s6p">
<title>Transmission electron microscopy</title>
<p><italic>Wild-type</italic> and <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors were fixed in culture plates overnight at 4 °C using 2.5% glutaraldehyde in 0.1 M Na cacodylate-HCl buffer (pH 7.2). After washing in 0.5 M Na cacodylate-HCl buffer (pH 7.0), the cells were post-fixed for 1 hr in 1% osmium tetroxide (w/v) at room temperature. After post-fixation, the culture plate with adherent cells were enblock stained (20 min) with 1% aqueous uranyl-acetate (w/v). Culture plates were washed again in the same buffer and dehydrated through a series of graded ethanol to 100% and transferred through two changes of 50/50 (v/v) SPIpon resin (Structure Probe, Inc.)/100% ethanol and left overnight to infiltrate. The following morning, the cell culture plates were transferred through three changes of fresh SPIpon resin to finish the infiltration and embedding and finally, the plates were filled with freshly prepared SPIpon resin and polymerized for 48 hrs at 70 °C.</p>
<p>Once fully polymerized, the plate was cut apart, and each well was plunged into liquid nitrogen to separate the SPIpon epoxy block with the embedded cells from the culture dish. The round epoxy disks with the embedded cells were then examined under an upright light microscope, and areas of cells were cut from the disks and glued onto blank microtome studs and trimmed for ultramicrotomy. Ultrathin sections (70 nm) were cut on a Reichart-Jung ultramicrotome using a diamond knife. The sections were collected and mounted on copper support grids and contrasted with lead citrate and uranyl acetate and examined on a FEI Tecnai G2 Spirit transmission electron microscope at 100 Kv accelerating voltage and images were recorded at various magnifications using a Gatan 2K digital camera system.</p>
</sec>
<sec id="s6q">
<title>Mitochondrial respiration</title>
<p>Mitochondrial respiration was examined in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors using a Seahorse XF<sup>e</sup>96 Extracellular Flux Analyzer (Agilent) as previously described [<xref ref-type="bibr" rid="c55">55</xref>]. Briefly, 10000 cells per well were seeded in XF 96-well culture plates and cultured overnight. The next day, cells were changed to assay medium and incubated at 37 °C w/o CO2 for 1 hr. The assay was carried out using the Seahorse XF Cell Mito Stress Test kit with sequential injections of Oligomycin (1 µM), FCCP (1 µM), and Rotenone plus Antimycin A (0.5 µM) following the manufacturer’s protocol.</p>
</sec>
<sec id="s6r">
<title>Senolytic treatments</title>
<p>For in vitro cell treatment, <italic>Chmp5<sup>Ctsk</sup></italic> and control cells were seeded in 96-well plates at a density of 6000 cells/ well and cultured overnight. Quercetin and dasatinib were added to the culture medium at a final concentration of 50 μM and 500 nM, respectively. Apoptotic cells are labeled using Incucyte Annexin V Red Dye and are quantified in real time using the Incucyte Live-Cell Analysis System. Six replicates were used for each group and the experiment was repeated twice using cells from two different animals per group.</p>
<p>For in vivo treatment, the senolytic drugs quercetin and dasatinib were administered intraperitoneally weekly at 50 µg/g and 5 µg/g body weight, respectively. Senolytic treatment in <italic>Chmp5<sup>Ctsk</sup></italic> and littermate control mice started from the first week after birth and mice were collected at 7-8 weeks of age for skeletal analyses. For the <italic>Chmp5<sup>Dmp1</sup></italic> strain, treatment began the second week after birth and the animals were monitored for 16 weeks. ABT-263 was administered intraperitoneally to <italic>Chmp5<sup>Ctsk</sup></italic> and littermate control mice weekly at 10 ug/g body weight, starting from the first week after birth and mice were collected at 8 weeks of age for micro-CT analyses.</p>
</sec>
<sec id="s6s">
<title>Statistics</title>
<p>All data are represented as mean ± s.d.. Normality and equal variance of the data sets were tested using the Shapiro-Wilk test and the F test, respectively. The data were determined to be normally distributed and have equal variance unless otherwise specified. For experiments with three or more groups, statistical analysis was performed using one-way or two-way ANOVA followed by multiple comparisons. For comparisons between two groups, the two-tailed unpaired Student’s <italic>t</italic>-test was applied. All analyses were performed with Prism 10.1.1 (GraphPad).</p>
</sec>
</sec>
</body>
<back>
<sec id="s7">
<title>Supplementary Figures</title>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S1.</label>
<caption><title>CHMP5 restricts bone formation in osteogenic lineage cells.</title><p>(<bold>A</bold>) Alizarin red staining of skeletal preparations on postnatal day 2. <italic>n</italic> = 4 mice per group. Scale bar, 1 mm. (<bold>B</bold>) Confocal images of <italic>Rosa26<sup>mTmG/+</sup></italic> (Cre<sup>−</sup>) control mice. Related to <xref rid="fig1" ref-type="fig">Fig. 1E</xref>. Scale bar, 200 μm. (<bold>C</bold>) Tartrate-resistant acid phosphatase (TRAP) staining demonstrating the absence of osteoclasts in peri-skeletal overgrowth (asterisk) of <italic>Chmp5<sup>Ctsk</sup></italic> mice at 2 weeks of age. TRAP<sup>+</sup> osteoclasts in the bone marrow as positive control; dot-line representing approximate border between peri-skeletal overgrowth and the bone at femoral condyle of the knee. Images are representative of 3 animals per group. Scale bar, 200 μm. (<bold>D</bold>) Gross image and measurement of femur thickness showing bone expansion in <italic>Chmp5<sup>Dmp1</sup></italic> versus <italic>Chmp5<sup>fl/fl</sup></italic> mice at 10 weeks of age. <italic>n</italic> = 13 <italic>Chmp5<sup>fl/fl</sup></italic> and 12 <italic>Chmp5<sup>Dmp1</sup></italic> mice. Scale bar, 1 mm. (<bold>E</bold>) H&amp;E histology showing bone expansion at the endosteum (arrows) in <italic>Chmp5<sup>Dmp1</sup></italic> mice. The left images showing the midshaft and the right images showing the metaphysis of the femur bone. Images are representative of 3 mice per group. Scale bars, 0.5 mm. Data are mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="233874v4_figs1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S2.</label>
<caption><title>Sorting of CD45<sup>−</sup>;CD31<sup>−</sup>;CTSK<sup>+</sup> periskeletal progenitors.</title><p>(<bold>A</bold>) Unstained cells from <italic>Rosa26-mTmG<sup>fl/+</sup></italic> mice as a negative control for sorting CD45<sup>−</sup>;CD31<sup>−</sup>;CTSK<sup>+</sup> skeletal progenitors. Related to <xref rid="fig2" ref-type="fig">Fig. 2A</xref>. (<bold>B</bold>) Quantification of CD45<sup>−</sup>;CD31<sup>−</sup>;GFP<sup>+</sup> and CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-cell population in samples of <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice. <italic>n</italic> = 10 mice per group.</p></caption>
<graphic xlink:href="233874v4_figs2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S3.</label>
<caption><title>Cell apoptosis is not the main cause of the decreased proliferative rate in <italic>Chmp5</italic>-deficient skeletal progenitors.</title><p>(<bold>A</bold>) Annexin V stain examining cellular apoptosis in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 3 replicates each group; repeated twice using cells from 2 mice per group. (<bold>B</bold>) TUNEL staining and quantification of TUNEL<sup>+</sup> cells (%) in the periskeletal tissues of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> mice. Arrows indicating positive cells in periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice, dot-line representing approximate border between periskeletal overgrowth and bone in the femoral condyle of the knee; <italic>n</italic> = 3 animals per group; scale bars, 100 μm. (<bold>C</bold>) GSEA of RNA-seq data showing significant enrichment of SAUL_SEN_MAYO and KAMMINGA_SENESCENCE genesets in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. (<bold>D</bold>) <italic>Cdkn1a</italic> and <italic>Cdkn2a</italic> mRNA levels in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors according to RNA-seq data. <italic>n</italic> = 3 per group with cells from 3 different animals. (<bold>E</bold>) Western blot confirming deletion of <italic>Chmp5</italic> in ATDC5 cells by lentiviral CRISPR/CAS9. (<bold>F</bold>) Cell number counting determining cell proliferation in ATDC5 cells after deleting <italic>Chmp5</italic> by lentiviral CRISPR/CAS9. <italic>n</italic> = 4 replicates per group per time point, experiment repeated three times. (<bold>G</bold>) Annexin V-PI stain analyzing cellular apoptosis in ATDC5 cells with or without <italic>Chmp5</italic> deletion. <italic>n</italic> = 3 replicates for each group, repeated 3 times. (<bold>H</bold>) Cell number counting determining cell proliferation in ATDC5 cells with or without <italic>Chmp5</italic> deletion after treatment with the pan-caspase inhibitor Q-VD-OPh. <italic>n</italic> = 3 replicates of each group each dose, repeated twice. All data are mean ± s.d.; two-tailed Student’s <italic>t</italic>-test for comparison of two groups or 2-way ANOVA followed by multiple comparisons.</p></caption>
<graphic xlink:href="233874v4_figs3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S4.</label>
<caption><title>Secretory phenotype of <italic>Chmp5</italic>-deficient skeletal progenitors.</title><p>(<bold>A</bold>) Nanoparticle tracking analysis showing the size distribution of extracellular vesicles in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> skeletal progenitors. Data pooled from 3 replicates, 5 reads for each; repeated twice using cells from 2 mice; D10, D50, and D90 indicating percent undersize, for example D50 = 229 nm representing that 50% of vesicles are 229 nm or smaller. (<bold>B</bold>) Alizarin red staining and quantification showing osteogenesis in coculture of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 3 replicates per group, repeated twice using cells from 2 different animals. (<bold>C</bold>) AlarmaBlue assay examining cell proliferation in neighboring CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-progenitors sorted from periskeletal tissues of <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> or <italic>Ctsk-Cre;Rosa26<sup>mTmG/+</sup></italic> mice. <italic>n</italic> = 12 replicates per group per time-point, repeated 3 times using cells from 3 animals. (<bold>D</bold>) Alizarin red staining determining osteogenesis in neighboring CD45<sup>−</sup>;CD31<sup>−</sup>;GFP-progenitors sorted from periskeletal tissues of <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> or <italic>Ctsk-Cre;Rosa26<sup>mTmG/+</sup></italic> mice after induction in osteogenic medium for 3 weeks. <italic>n</italic> = 3 replicates per group per time point, repeated 3 times using cells from 3 animals. (<bold>E</bold>) Immunostaining and quantification of cell proliferation marker Ki-67 in the periskeletal tissues around the knee of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup></italic> mice. <italic>n</italic> = 3 animals per group; dot-line representing the approximate border between the periskeletal overgrowth and the bone in the femoral condyle; scale bars, 100 μm. (<bold>F</bold>) Heatmap of LC-MS/MS results showing differentially secreted proteins in supernatants of <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>wild-type</italic> skeletal progenitors. <italic>n</italic> = 3 with cells from 3 different animals per group for Nano LC-MS/MS analysis. All data are mean ± s.d., 2-way ANOVA followed by multiple comparisons or two-tailed unpaired Student’s <italic>t</italic>-test for 2-group comparison.</p></caption>
<graphic xlink:href="233874v4_figs4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S5.</label>
<caption><title>Additional x-ray images of <italic>Chmp5<sup>Ctsk</sup></italic> mice after treatment with Q + D or the vehicle PEG400 for 7 weeks.</title>
<p>Arrows indicating periskeletal bone overgrowths.</p></caption>
<graphic xlink:href="233874v4_figs5.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S6.</label>
<caption><title>CHMP5 is essential for endolysosomal functions and maintaining VPS4A protein in skeletal progenitors.</title><p>(<bold>A</bold>) Representative confocal fluorescence images and quantification of the fluorescence intensity of LysoTracker Red DND-99 in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 11 replicates per group for quantitative analysis; repeated 3 times using cells from 3 mice. Scale bars, 50 μm. (<bold>B</bold>) Isotype controls for immunofluorescence staining. Scale bars, 20 μm. (<bold>C</bold>) Co-localization of LAMP1 and RAB7 in <italic>Chmp5</italic>-sufficient or <italic>Chmp5</italic>-deficient ATDC5 cells. Scale bars, 10 μm. (<bold>D</bold>) Colocalization analysis of LAMP1 and RAB7 performed by the ImageJ Coloc2 programme and Pearson’s R value (above threshold) shown, <italic>n</italic> = 20 cells per group. (<bold>E</bold>) Representative confocal images of immunostaining for early endosome marker EEA1, cycling endosome marker RAB11, and trans-Golgi network marker TGN38 in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> periskeletal progenitors. <italic>n</italic> = 30 cells per group. Scale bars, 10 μm (EEA1), 20 μm (RAB11), 25 μm (TGN38). (<bold>F</bold>) RNA-seq data showing <italic>Vps4a</italic> mRNA expression in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 3 with cells from 3 different animals for each group. (<bold>G</bold>) Western blot showing that CHMP5 and VPS4A protein expression after transfection of CHMP5 or empty vector in HEK-293T cells. Experiments repeated 3 times with independent cells and transfections at different times. (<bold>H</bold>) Quantitative PCR showing the expression of <italic>CHMP5</italic> and <italic>VPS4A</italic> mRNA after transfecting CHMP5 or empty vector in HEK-293T cells. <italic>n</italic> = 3 replicates for each group, experiments repeated 3 times with independent cells and transfections at different times. All data shown as mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="233874v4_figs6.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Fig. S7.</label>
<caption><title>Mitochondrial dysfunction and activation of DNA damage-induced senescence in <italic>Chmp5</italic>-deficient skeletal progenitors.</title><p>(<bold>A</bold>) Representative TMRE confocal images showing accumulation of mitochondria in <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors. <italic>n</italic> = 30 cells per group, scale bars, 25 μm. (<bold>B</bold>) Confocal fluorescence imaging mapping intracellular ROS (CellROX Deep Red) and mitochondria (MitoTracker Green) in ATDC5 cells with or without <italic>Chmp5</italic> depletion. <italic>n</italic> = 20 cells for each group; scale bars, 10 μm. The right histogram showing the quantification of CellROX Deep Red in ATDC5 cells by flow cytometry. <italic>n</italic> = 3 per group, experiment repeated twice. (<bold>C</bold>) GSEA of RNA-seq data showing positive enrichment of genes associated with the molecular pathway of DNA damage-induced senescence in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. (<bold>D</bold>) Quantitative PCR determining expression of <italic>H2afx</italic> and <italic>Trp53</italic> genes in <italic>Chmp5<sup>Ctsk</sup></italic> relative to <italic>Chmp5<sup>Ctsk/+</sup></italic> periskeletal progenitors. <italic>n</italic> = 6 with cells from different animals per group. Data shown as mean ± s.d.; two-tailed unpaired Student’s <italic>t</italic>-test.</p></caption>
<graphic xlink:href="233874v4_figs7.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Dr. Sankar Ghosh for providing <italic>Chmp5</italic>-floxed mice; Drs. Gregory Hendricks and Lara Strittmatter at the University of Massachusetts Chan Medical School for help in interpreting TEM data; Dr. Tomer Shpilka for assistance in running the Seahorse analyzer; Drs. Guangchuang Yu and Jiyeon Park for independently analyzing the RNA-seq data. Dr. Chunjing Bian for generating the CHMP5 overexpression vector. X.G. is supported by the National Natural Science Foundation of China (project 2-2-008-0213) and the Beijing Natural Science Foundation (project 5222008). J.H.S. holds support from the NIH (R21AR077557, R01AR078230) and AAVAA Therapeutics.</p>
</ack>
<sec id="d1e2670" sec-type="additional-information">
<title>Additional information</title>
<sec id="s4">
<title>Contributions</title>
<p>X.G. perceived the project, designed experiments, interpreted the results, and wrote and reviewed the manuscript; F.Z., Y.W., L.Z., C.W. and X.G. performed experiments and analyzed the results; D.C. and R.X. provided critical resources for the study; H.L. contributed to part of RNA-seq data analyses; C.M.H. offered suggestions and main reagents for mitochondrial analyses; J.H.S. partly supported the study and reviewed the manuscript.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaksonen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Roux</surname> <given-names>A</given-names></string-name></person-group>. <article-title>Mechanisms of clathrin-mediated endocytosis</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2018</year>;<volume>19</volume>(<issue>5</issue>):<fpage>313</fpage>–<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Christ</surname> <given-names>L</given-names></string-name>, <string-name><surname>Raiborg</surname> <given-names>C</given-names></string-name>, <string-name><surname>Wenzel</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Campsteijn</surname> <given-names>C</given-names></string-name>, <string-name><surname>Stenmark</surname> <given-names>H</given-names></string-name></person-group>. <article-title>Cellular Functions and Molecular Mechanisms of the ESCRT Membrane-Scission Machinery</article-title>. <source>Trends Biochem Sci</source>. <year>2017</year>;<volume>42</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luzio</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Pryor</surname> <given-names>PR</given-names></string-name>, <string-name><surname>Bright</surname> <given-names>NA</given-names></string-name></person-group>. <article-title>Lysosomes: fusion and function</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2007</year>;<volume>8</volume>(<issue>8</issue>):<fpage>622</fpage>–<lpage>32</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hurley</surname> <given-names>JH</given-names></string-name></person-group>. <article-title>ESCRTs are everywhere</article-title>. <source>EMBO J</source>. <year>2015</year>;<volume>34</volume>(<issue>19</issue>):<fpage>2398</fpage>–<lpage>407</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmidt</surname> <given-names>O</given-names></string-name>, <string-name><surname>Teis</surname> <given-names>D</given-names></string-name></person-group>. <article-title>The ESCRT machinery</article-title>. <source>Curr Biol</source>. <year>2012</year>;<volume>22</volume>(<issue>4</issue>):<fpage>R116</fpage>–<lpage>20</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shim</surname> <given-names>JH</given-names></string-name>, <string-name><surname>Xiao</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hayden</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Trombetta</surname> <given-names>ES</given-names></string-name>, <string-name><surname>Pypaert</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CHMP5 is essential for late endosome function and down-regulation of receptor signaling during mouse embryogenesis</article-title>. <source>J Cell Biol</source>. <year>2006</year>;<volume>172</volume>(<issue>7</issue>):<fpage>1045</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kranz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kinner</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kolling</surname> <given-names>R</given-names></string-name></person-group>. <article-title>A family of small coiled-coil-forming proteins functioning at the late endosome in yeast</article-title>. <source>Mol Biol Cell</source>. <year>2001</year>;<volume>12</volume>(<issue>3</issue>):<fpage>711</fpage>–<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Greenblatt</surname> <given-names>MB</given-names></string-name>, <string-name><surname>Park</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Oh</surname> <given-names>H</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Shin</surname> <given-names>DY</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>JM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>CHMP5 controls bone turnover rates by dampening NF-kappaB activity in osteoclasts</article-title>. <source>J Exp Med</source>. <year>2015</year>;<volume>212</volume>(<issue>8</issue>):<fpage>1283</fpage>–<lpage>301</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Adoro</surname> <given-names>S</given-names></string-name>, <string-name><surname>Park</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Bettigole</surname> <given-names>SE</given-names></string-name>, <string-name><surname>Lis</surname> <given-names>R</given-names></string-name>, <string-name><surname>Shin</surname> <given-names>HR</given-names></string-name>, <string-name><surname>Seo</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Post-translational control of T cell development by the ESCRT protein CHMP5</article-title>. <source>Nat Immunol</source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>780</fpage>–<lpage>90</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parenti</surname> <given-names>G</given-names></string-name>, <string-name><surname>Medina</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Ballabio</surname> <given-names>A</given-names></string-name></person-group>. <article-title>The rapidly evolving view of lysosomal storage diseases</article-title>. <source>EMBO Mol Med</source>. <year>2021</year>;<volume>13</volume>(<issue>2</issue>):<fpage>e12836</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morishita</surname> <given-names>K</given-names></string-name>, <string-name><surname>Petty</surname> <given-names>RE</given-names></string-name></person-group>. <article-title>Musculoskeletal manifestations of mucopolysaccharidoses</article-title>. <source>Rheumatology (Oxford)</source>. <year>2011</year>;<volume>50</volume> <issue>Suppl 5</issue>:<fpage>v19</fpage>–<lpage>25</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarke</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Hollak</surname> <given-names>CE</given-names></string-name></person-group>. <article-title>The clinical spectrum and pathophysiology of skeletal complications in lysosomal storage disorders</article-title>. <source>Best Pract Res Clin Endocrinol Metab</source>. <year>2015</year>;<volume>29</volume>(<issue>2</issue>):<fpage>219</fpage>–<lpage>35</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname> <given-names>BS</given-names></string-name>, <string-name><surname>Fung</surname> <given-names>EB</given-names></string-name>, <string-name><surname>White</surname> <given-names>KK</given-names></string-name>, <string-name><surname>Lund</surname> <given-names>TC</given-names></string-name>, <string-name><surname>Harmatz</surname> <given-names>P</given-names></string-name>, <string-name><surname>Orchard</surname> <given-names>PJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Persistent bone and joint disease despite current treatments for mucopolysaccharidosis types I, II, and VI: Data from a 10-year prospective study</article-title>. <source>J Inherit Metab Dis.</source> <year>2023</year>;<volume>46</volume>(<issue>4</issue>):<fpage>695</fpage>–<lpage>704</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>W</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Liang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Dooner</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>Q</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling</article-title>. <source>Nature</source>. <year>2013</year>;<volume>499</volume>(<issue>7459</issue>):<fpage>491</fpage>-<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Debnath</surname> <given-names>S</given-names></string-name>, <string-name><surname>Yallowitz</surname> <given-names>AR</given-names></string-name>, <string-name><surname>McCormick</surname> <given-names>J</given-names></string-name>, <string-name><surname>Lalani</surname> <given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>T</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>R</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Discovery of a periosteal stem cell mediating intramembranous bone formation</article-title>. <source>Nature</source>. <year>2018</year>;<volume>562</volume>(<issue>7725</issue>):<fpage>133</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="preprint"><person-group person-group-type="author"><string-name><surname>Shi</surname> <given-names>R</given-names></string-name>, <string-name><surname>He</surname> <given-names>L</given-names></string-name>, <string-name><surname>Ren</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hou</surname> <given-names>G</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>A migratory stem cell population for musculoskeletal enveloping tissues and the bone</article-title>. <source>SSRN</source> <elocation-id>3281656</elocation-id>, <year>2018</year>. (<pub-id pub-id-type="doi">10.2139/ssrn.3281656</pub-id>).</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Logan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Martin</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Nagy</surname> <given-names>A</given-names></string-name>, <string-name><surname>Lobe</surname> <given-names>C</given-names></string-name>, <string-name><surname>Olson</surname> <given-names>EN</given-names></string-name>, <string-name><surname>Tabin</surname> <given-names>CJ</given-names></string-name></person-group>. <article-title>Expression of Cre Recombinase in the developing mouse limb bud driven by a Prxl enhancer</article-title>. <source>Genesis</source>. <year>2002</year>;<volume>33</volume>(<issue>2</issue>):<fpage>77</fpage>–<lpage>80</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ono</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ono</surname> <given-names>W</given-names></string-name>, <string-name><surname>Mizoguchi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Nagasawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Frenette</surname> <given-names>PS</given-names></string-name>, <string-name><surname>Kronenberg</surname> <given-names>HM</given-names></string-name></person-group>. <article-title>Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage</article-title>. <source>Dev Cell</source>. <year>2014</year>;<volume>29</volume>(<issue>3</issue>):<fpage>330</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maes</surname> <given-names>C</given-names></string-name>, <string-name><surname>Kobayashi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Selig</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Torrekens</surname> <given-names>S</given-names></string-name>, <string-name><surname>Roth</surname> <given-names>SI</given-names></string-name>, <string-name><surname>Mackem</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Osteoblast precursors, but not mature osteoblasts, move into developing and fractured bones along with invading blood vessels</article-title>. <source>Dev Cell</source>. <year>2010</year>;<volume>19</volume>(<issue>2</issue>):<fpage>329</fpage>–<lpage>44</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lim</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Karner</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>WC</given-names></string-name>, <string-name><surname>He</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Dual function of Bmpr1a signaling in restricting preosteoblast proliferation and stimulating osteoblast activity in mouse</article-title>. <source>Development</source>. <year>2016</year>;<volume>143</volume>(<issue>2</issue>):<fpage>339</fpage>–<lpage>47</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lim</surname> <given-names>J</given-names></string-name>, <string-name><surname>Burclaff</surname> <given-names>J</given-names></string-name>, <string-name><surname>He</surname> <given-names>G</given-names></string-name>, <string-name><surname>Mills</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Long</surname> <given-names>F</given-names></string-name></person-group>. <article-title>Unintended targeting of Dmp1-Cre reveals a critical role for Bmpr1a signaling in the gastrointestinal mesenchyme of adult mice</article-title>. <source>Bone Res</source>. <year>2017</year>;<volume>5</volume>:<issue>16049</issue>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matic</surname> <given-names>I</given-names></string-name>, <string-name><surname>Matthews</surname> <given-names>BG</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Dyment</surname> <given-names>NA</given-names></string-name>, <string-name><surname>Worthley</surname> <given-names>DL</given-names></string-name>, <string-name><surname>Rowe</surname> <given-names>DW</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Quiescent Bone Lining Cells Are a Major Source of Osteoblasts During Adulthood</article-title>. <source>Stem Cells</source>. <year>2016</year>;<volume>34</volume>(<issue>12</issue>):<fpage>2930</fpage>–<lpage>42</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ge</surname> <given-names>X</given-names></string-name>, <string-name><surname>Tsang</surname> <given-names>K</given-names></string-name>, <string-name><surname>He</surname> <given-names>L</given-names></string-name>, <string-name><surname>Garcia</surname> <given-names>RA</given-names></string-name>, <string-name><surname>Ermann</surname> <given-names>J</given-names></string-name>, <string-name><surname>Mizoguchi</surname> <given-names>F</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>NFAT restricts osteochondroma formation from entheseal progenitors</article-title>. <source>JCI Insight</source>. <year>2016</year>;<volume>1</volume>(<issue>4</issue>):<fpage>e86254</fpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birch</surname> <given-names>J</given-names></string-name>, <string-name><surname>Gil</surname> <given-names>J</given-names></string-name></person-group>. <article-title>Senescence and the SASP: many therapeutic avenues</article-title>. <source>Genes Dev</source>. <year>2020</year>;<volume>34</volume>(<issue>23-24</issue>):<fpage>1565</fpage>–<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Romanello</surname> <given-names>M</given-names></string-name>, <string-name><surname>Piatkowska</surname> <given-names>E</given-names></string-name>, <string-name><surname>Antoniali</surname> <given-names>G</given-names></string-name>, <string-name><surname>Cesaratto</surname> <given-names>L</given-names></string-name>, <string-name><surname>Vascotto</surname> <given-names>C</given-names></string-name>, <string-name><surname>Iozzo</surname> <given-names>RV</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment</article-title>. <source>Bone</source>. <year>2014</year>;<volume>58</volume>:<fpage>81</fpage>–<lpage>91</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davies</surname> <given-names>OG</given-names></string-name>, <string-name><surname>Cox</surname> <given-names>SC</given-names></string-name>, <string-name><surname>Azoidis</surname> <given-names>I</given-names></string-name>, <string-name><surname>McGuinness</surname> <given-names>AJA</given-names></string-name>, <string-name><surname>Cooke</surname> <given-names>M</given-names></string-name>, <string-name><surname>Heaney</surname> <given-names>LM</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Osteoblast-Derived Vesicle Protein Content Is Temporally Regulated During Osteogenesis: Implications for Regenerative Therapies</article-title>. <source>Front Bioeng Biotechnol</source>. <year>2019</year>;<volume>7</volume>:<issue>92</issue>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Tchkonia</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pirtskhalava</surname> <given-names>T</given-names></string-name>, <string-name><surname>Gower</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Ding</surname> <given-names>H</given-names></string-name>, <string-name><surname>Giorgadze</surname> <given-names>N</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs</article-title>. <source>Aging Cell</source>. <year>2015</year>;<volume>14</volume>(<issue>4</issue>):<fpage>644</fpage>–<lpage>58</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickson</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Langhi Prata</surname> <given-names>LGP</given-names></string-name>, <string-name><surname>Bobart</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Evans</surname> <given-names>TK</given-names></string-name>, <string-name><surname>Giorgadze</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hashmi</surname> <given-names>SK</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease</article-title>. <source>EBioMedicine</source>. <year>2019</year>;<volume>47</volume>:<fpage>446</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tse</surname> <given-names>C</given-names></string-name>, <string-name><surname>Shoemaker</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Adickes</surname> <given-names>J</given-names></string-name>, <string-name><surname>Anderson</surname> <given-names>MG</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>J</given-names></string-name>, <string-name><surname>Jin</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor</article-title>. <source>Cancer Res</source>. <year>2008</year>;<volume>68</volume>(<issue>9</issue>):<fpage>3421</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname> <given-names>J</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shao</surname> <given-names>L</given-names></string-name>, <string-name><surname>Laberge</surname> <given-names>RM</given-names></string-name>, <string-name><surname>Demaria</surname> <given-names>M</given-names></string-name>, <string-name><surname>Campisi</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>(<issue>1</issue>):<fpage>78</fpage>–<lpage>83</lpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martini</surname> <given-names>H</given-names></string-name>, <string-name><surname>Passos</surname> <given-names>JF</given-names></string-name></person-group>. <article-title>Cellular senescence: all roads lead to mitochondria</article-title>. <source>Febs J</source>. <year>2023</year>;<volume>290</volume>(<issue>5</issue>):<fpage>1186</fpage>–<lpage>202</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>YS</given-names></string-name>, <string-name><surname>Cho</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Park</surname> <given-names>SC</given-names></string-name></person-group>. <article-title>Adjustment of the lysosomal-mitochondrial axis for control of cellular senescence</article-title>. <source>Ageing Res Rev</source>. <year>2018</year>;<volume>47</volume>:<fpage>176</fpage>–<lpage>82</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gorgoulis</surname> <given-names>V</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Alimonti</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bennett</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Bischof</surname> <given-names>O</given-names></string-name>, <string-name><surname>Bishop</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Cellular Senescence: Defining a Path Forward</article-title>. <source>Cell</source>. <year>2019</year>;<volume>179</volume>(<issue>4</issue>):<fpage>813</fpage>–<lpage>27</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Korolchuk</surname> <given-names>VI</given-names></string-name>, <string-name><surname>Miwa</surname> <given-names>S</given-names></string-name>, <string-name><surname>Carroll</surname> <given-names>B</given-names></string-name>, <string-name><surname>von Zglinicki</surname> <given-names>T</given-names></string-name></person-group>. <article-title>Mitochondria in Cell Senescence: Is Mitophagy the Weakest Link?</article-title> <source>EBioMedicine</source>. <year>2017</year>;<volume>21</volume>:<fpage>7</fpage>–<lpage>13</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birch</surname> <given-names>J</given-names></string-name>, <string-name><surname>Passos</surname> <given-names>JF</given-names></string-name></person-group>. <article-title>Targeting the SASP to combat ageing: Mitochondria as possible intracellular allies?</article-title> <source>Bioessays</source>. <year>2017</year>;<volume>39</volume>(<issue>5</issue>).</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paramos-de-Carvalho</surname> <given-names>D</given-names></string-name>, <string-name><surname>Jacinto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Saude</surname> <given-names>L</given-names></string-name></person-group>. <article-title>The right time for senescence</article-title>. <source>eLife</source>. <year>2021</year>;<volume>10</volume>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiley</surname> <given-names>CD</given-names></string-name>, <string-name><surname>Campisi</surname> <given-names>J</given-names></string-name></person-group>. <article-title>The metabolic roots of senescence: mechanisms and opportunities for intervention</article-title>. <source>Nat Metab</source>. <year>2021</year>;<volume>3</volume>(<issue>10</issue>):<fpage>1290</fpage>–<lpage>301</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martini</surname> <given-names>H</given-names></string-name>, <string-name><surname>Passos</surname> <given-names>JF</given-names></string-name></person-group>. <article-title>Cellular senescence: all roads lead to mitochondria</article-title>. <source>Febs J</source>. <year>2022</year>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vild</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>EZ</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>Z</given-names></string-name></person-group>. <article-title>A novel mechanism of regulating the ATPase VPS4 by its cofactor LIP5 and the endosomal sorting complex required for transport (ESCRT)-III protein CHMP5</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>11</issue>):<fpage>7291</fpage>–<lpage>303</lpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Vild</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ju</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Liu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Structural basis of molecular recognition between ESCRT-III-like protein Vps60 and AAA-ATPase regulator Vta1 in the multivesicular body pathway</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>52</issue>):<fpage>43899</fpage>–<lpage>908</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodger</surname> <given-names>C</given-names></string-name>, <string-name><surname>Flex</surname> <given-names>E</given-names></string-name>, <string-name><surname>Allison</surname> <given-names>RJ</given-names></string-name>, <string-name><surname>Sanchis-Juan</surname> <given-names>A</given-names></string-name>, <string-name><surname>Hasenahuer</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Cecchetti</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment</article-title>. <source>Am J Hum Genet</source>. <year>2020</year>;<volume>107</volume>(<issue>6</issue>):<fpage>1129</fpage>–<lpage>48</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salazar</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Duhnam-Ems</surname> <given-names>S</given-names></string-name>, <string-name><surname>La Vake</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cruz</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Moore</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Caimano</surname> <given-names>MJ</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and -independent responses which include induction of IFN-beta</article-title>. <source>PLoS Pathog</source>. <year>2009</year>;<volume>5</volume>(<issue>5</issue>):<fpage>e1000444</fpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thiebaut</surname> <given-names>R</given-names></string-name>, <string-name><surname>Esmiol</surname> <given-names>S</given-names></string-name>, <string-name><surname>Lecine</surname> <given-names>P</given-names></string-name>, <string-name><surname>Mahfouz</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hermant</surname> <given-names>A</given-names></string-name>, <string-name><surname>Nicoletti</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Characterization and Genetic Analyses of New Genes Coding for NOD2 Interacting Proteins</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>11</issue>):<fpage>e0165420</fpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dai</surname> <given-names>GC</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ming</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lu</surname> <given-names>PP</given-names></string-name>, <string-name><surname>Li</surname> <given-names>YJ</given-names></string-name>, <string-name><surname>Gao</surname> <given-names>YC</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Heterotopic mineralization (ossification or calcification) in aged musculoskeletal soft tissues: A new candidate marker for aging</article-title>. <source>Ageing Res Rev</source>. <year>2024</year>;<volume>95</volume>:<issue>102215</issue>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Xie</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>S</given-names></string-name>, <string-name><surname>Dusevich</surname> <given-names>V</given-names></string-name>, <string-name><surname>Bonewald</surname> <given-names>LF</given-names></string-name>, <string-name><surname>Feng</surname> <given-names>JQ</given-names></string-name></person-group>. <article-title>DMP1-targeted Cre expression in odontoblasts and osteocytes</article-title>. <source>J Dent Res</source>. <year>2007</year>;<volume>86</volume>(<issue>4</issue>):<fpage>320</fpage>–<lpage>5</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rodda</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>McMahon</surname> <given-names>AP</given-names></string-name></person-group>. <article-title>Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors</article-title>. <source>Development</source>. <year>2006</year>;<volume>133</volume>(<issue>16</issue>):<fpage>3231</fpage>–<lpage>44</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nakamura</surname> <given-names>T</given-names></string-name>, <string-name><surname>Imai</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Matsumoto</surname> <given-names>T</given-names></string-name>, <string-name><surname>Sato</surname> <given-names>S</given-names></string-name>, <string-name><surname>Takeuchi</surname> <given-names>K</given-names></string-name>, <string-name><surname>Igarashi</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts</article-title>. <source>Cell</source>. <year>2007</year>;<volume>130</volume>(<issue>5</issue>):<fpage>811</fpage>–<lpage>23</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bonetto</surname> <given-names>A</given-names></string-name>, <string-name><surname>Andersson</surname> <given-names>DC</given-names></string-name>, <string-name><surname>Waning</surname> <given-names>DL</given-names></string-name></person-group>. <article-title>Assessment of muscle mass and strength in mice</article-title>. <source>Bonekey Rep</source>. <year>2015</year>;<volume>4</volume>:<fpage>732</fpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Takeshita</surname> <given-names>H</given-names></string-name>, <string-name><surname>Yamamoto</surname> <given-names>K</given-names></string-name>, <string-name><surname>Nozato</surname> <given-names>S</given-names></string-name>, <string-name><surname>Inagaki</surname> <given-names>T</given-names></string-name>, <string-name><surname>Tsuchimochi</surname> <given-names>H</given-names></string-name>, <string-name><surname>Shirai</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice</article-title>. <source>Sci Rep</source>. <year>2017</year>;<volume>7</volume>:<fpage>42323</fpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Langmead</surname> <given-names>B</given-names></string-name>, <string-name><surname>Salzberg</surname> <given-names>SL</given-names></string-name></person-group>. <article-title>Fast gapped-read alignment with Bowtie 2</article-title>. <source>Nat Methods</source>. <year>2012</year>;<volume>9</volume>(<issue>4</issue>):<fpage>357</fpage>–<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dobin</surname> <given-names>A</given-names></string-name>, <string-name><surname>Davis</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Schlesinger</surname> <given-names>F</given-names></string-name>, <string-name><surname>Drenkow</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zaleski</surname> <given-names>C</given-names></string-name>, <string-name><surname>Jha</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>STAR: ultrafast universal RNA-seq aligner</article-title>. <source>Bioinformatics</source>. <year>2013</year>;<volume>29</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>21</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trapnell</surname> <given-names>C</given-names></string-name>, <string-name><surname>Hendrickson</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Sauvageau</surname> <given-names>M</given-names></string-name>, <string-name><surname>Goff</surname> <given-names>L</given-names></string-name>, <string-name><surname>Rinn</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Pachter</surname> <given-names>L</given-names></string-name></person-group>. <article-title>Differential analysis of gene regulation at transcript resolution with RNA-seq</article-title>. <source>Nat Biotechnol</source>. <year>2013</year>;<volume>31</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>53</lpage>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fabregat</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sidiropoulos</surname> <given-names>K</given-names></string-name>, <string-name><surname>Viteri</surname> <given-names>G</given-names></string-name>, <string-name><surname>Forner</surname> <given-names>O</given-names></string-name>, <string-name><surname>Marin-Garcia</surname> <given-names>P</given-names></string-name>, <string-name><surname>Arnau</surname> <given-names>V</given-names></string-name>, <etal>et al.</etal></person-group> <article-title>Reactome pathway analysis: a high-performance in-memory approach</article-title>. <source>BMC Bioinformatics</source>. <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<fpage>142</fpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schmittgen</surname> <given-names>TD</given-names></string-name>, <string-name><surname>Livak</surname> <given-names>KJ</given-names></string-name></person-group>. <article-title>Analyzing real-time PCR data by the comparative C(T) method</article-title>. <source>Nat Protoc</source>. <year>2008</year>;<volume>3</volume>(<issue>6</issue>):<fpage>1101</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fiorese</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Schulz</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>YF</given-names></string-name>, <string-name><surname>Rosin</surname> <given-names>N</given-names></string-name>, <string-name><surname>Pellegrino</surname> <given-names>MW</given-names></string-name>, <string-name><surname>Haynes</surname> <given-names>CM</given-names></string-name></person-group>. <article-title>The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR</article-title>. <source>Curr Biol</source>. <year>2016</year>;<volume>26</volume>(<issue>15</issue>):<fpage>2037</fpage>–<lpage>43</lpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101984.2.sa3</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Mei</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Johns Hopkins University</institution>
</institution-wrap>
<city>Baltimore</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Convincing</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> work advances our understanding of CHMP5's role in regulating osteogenesis through its impact on cellular senescence. The evidence supporting the conclusion is <bold>convincing</bold> and the revised manuscript is largely improved. This paper holds potential interest for skeletal biologists who study the pathogenesis of age-associated skeletal disorders.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101984.2.sa2</article-id>
<title-group>
<article-title>Reviewer #1 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The manuscript presents a significant and rigorous investigation into the role of CHMP5 in regulating bone formation and cellular senescence. The study provides compelling evidence that CHMP5 is essential for maintaining endolysosomal function and controlling mitochondrial ROS levels, thereby preventing the senescence of skeletal progenitor cells.</p>
<p>Strengths:</p>
<p>The authors demonstrate that the deletion of Chmp5 results in endolysosomal dysfunction, elevated mitochondrial ROS, and ultimately enhanced bone formation through both autonomous and paracrine mechanisms. The innovative use of senolytic drugs to ameliorate musculoskeletal abnormalities in Chmp5-deficient mice is a novel and critical finding, suggesting potential therapeutic strategies for musculoskeletal disorders linked to endolysosomal dysfunction.</p>
<p>Comments on the latest version:</p>
<p>My concerns were addressed.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101984.2.sa1</article-id>
<title-group>
<article-title>Reviewer #3 (Public review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>In this study, Zhang et al., reported that CHMP5 restricts bone formation by controlling endolysosome-mitochondrion-mediated cell senescence. Zhang et al., report a novel role of CHMP5 on osteogenesis through affecting cell senescence. Overall, it is an interesting study and provides new insights in the field of cells senescence and bone.</p>
<p>Strengths:</p>
<p>Analyzed the bone phenotype OF CHMP5-periskeletal progenitor-CKO mouse model and found the novel role of senescent cells on osteogenesis and migration.</p>
<p>Weaknesses:</p>
<p>(1) The role and mechanism of CHMP5 gene deletion in enhancing osteogenesis via cellular senescence remain insufficiently elucidated.</p>
<p>(2) The use of the ADTC5 cell line as a skeletal precursor/progenitor model is suboptimal.</p>
<p>Overall, the results support their conclusions.</p>
<p>The impact of this work on the field is its proposal that cellular senescence may exert either inhibitory or promotive effects on osteogenic capacity, depending on cell type and context.</p>
<p>The revised manuscript has addressed most of the concerns raised during the initial review.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.101984.2.sa0</article-id>
<title-group>
<article-title>Author response:</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Fan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yuan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Luyang</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chunjie</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Deping</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Haibo</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xu</surname>
<given-names>Ren</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haynes</surname>
<given-names>Cole M</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shim</surname>
<given-names>Jae-Hyuck</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ge</surname>
<given-names>Xianpeng</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1291-2096</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews</p>
<disp-quote content-type="editor-comment">
<p><bold>Public Reviews:</bold></p>
<p><bold>Reviewer #1 (Public review):</bold></p>
<p>Summary:</p>
<p>The manuscript presents a significant and rigorous investigation into the role of CHMP5 in regulating bone formation and cellular senescence. The study provides compelling evidence that CHMP5 is essential for maintaining endolysosomal function and controlling mitochondrial ROS levels, thereby preventing the senescence of skeletal progenitor cells.</p>
<p>Strengths:</p>
<p>The authors demonstrate that the deletion of Chmp5 results in endolysosomal dysfunction, elevated mitochondrial ROS, and ultimately enhanced bone formation through both autonomous and paracrine mechanisms. The innovative use of senolytic drugs to ameliorate musculoskeletal abnormalities in Chmp5-deficient mice is a novel and critical finding, suggesting potential therapeutic strategies for musculoskeletal disorders linked to endolysosomal dysfunction.</p>
<p>Weaknesses:</p>
<p>The manuscript requires a deeper discussion or exploration of CHMP5's roles and a more refined analysis of senolytic drug specificity and effects. This would greatly enhance the comprehensiveness and clarity of the manuscript.</p>
</disp-quote>
<p>We thank the reviewer for these insightful comments. In the revised manuscript, we have expanded the discussion of the distinct roles of CHMP5 in different cell types. Specifically, we add the following sentences (Lines 433-439 in the combined manuscript):</p>
<p>“Also, a previous study by Adoro et al. did not detect endolysosomal abnormalities in Chmp5 deficient developmental T cells [1]. Since both osteoclasts and T cells are of hematopoietic origin, and meanwhile osteogenic cells and MEFs, which show endolysosomal abnormalities after CHMP5 deficiency, are of mesenchymal origin, it turns out that the function of CHMP5 in regulating endolysosomal pathway could be cell lineage-specific, which remains clarified in future studies.”</p>
<p>In addition, we tested another senolytic drug Navitoclax (ABT-263), which is a BCL-2 family inhibitor and induces apoptosis of senescent cells, in <italic>Chmp5<sup>Ctsk</sup></italic> mice. Micro-CT analysis showed that ABT-263 could also improve periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Fig. 5F). Furthermore, we have also discussed the potential off-target effects of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice in the revised manuscript. Specifically, we added the following paragraph (Lines 441-451):</p>
<p>“Furthermore, it is unclear whether the effect of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice involves targeting osteoclasts other than osteogenic cells, as osteoclast senescence has not yet been evaluated. However, the efficacy of Q + D in targeting osteogenic cells, which is the focus of the current study, was confirmed in <italic>Chmp5<sup>Dmp1</sup></italic> mice (Fig. 5C-E). Additionally, Q + D caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors in ex vivo culture (Fig. 5A), demonstrating the effectiveness of Q + D in targeting osteogenic cells in the <italic>Chmp5<sup>Ctsk</sup></italic> model. Furthermore, an alternative senolytic drug ABT-263 could also ameliorate periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Fig. 5F). Together, these results confirm that osteogenic cell senescence is responsible for the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice, and senolytic treatments are effective in alleviating these skeletal disorders.”</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Public review):</bold></p>
<p>Summary:</p>
<p>The authors try to show the importance of CHMP5 for skeletal development.</p>
<p>Strengths:</p>
<p>The findings of this manuscript are interesting. The mouse phenotypes are well done and are of interest to a broader (bone) field.</p>
<p>Weaknesses:</p>
<p>The mechanistic insights are mediocre, and the cellular senescence aspect poor.</p>
<p>In total, it has not been shown that there are actual senescent cells that are reduced after D+Qtreatment. These statements need to be scaled back substantially.</p>
</disp-quote>
<p>We thank the reviewer for these suggestive comments. We have added additional results to strengthen the senescent phenotypes of <italic>Chmp5</italic>-deficient skeletal progenitor cells, including significant enrichment of the SAUL_SEN_MAYO geneset (positively correlated with cell senescence) and the KAMMINGA_SENESCENCE geneset (negatively correlated with cell senescence) at the transcriptional level by GSEA analysis of RNA-seq data (Fig. S3C), and the increase of γH2Ax<sup>+</sup>;GFP<sup>+</sup> cells at periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice vs. the periosteum of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> control mice (Fig. 3E). These results further advocate for the senescent phenotypes of <italic>Chmp5</italic>-deficient skeletal progenitors.</p>
<p>Furthermore, the combination of Q + D caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wildtype</italic> periskeletal progenitors in ex vivo culture (Fig. 5A), suggesting their effectiveness in targeting periskeletal progenitor cell senescence in <italic>Chmp5<sup>Ctsk</sup></italic> mice. Furthermore, we tested an alternative senolytic drug ABT-263, which is an inhibitor of the BCL-2 family and induces apoptosis of senescent cells, in <italic>Chmp5<sup>Ctsk</sup></italic> mice, and ABT-263 could also alleviate periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Fig. 5F). Together, these results demonstrate that osteogenic cell senescence is responsible for abnormal bone overgrowth in <italic>Chmp5</italic>-deficient mice and that senolytic drugs are effective in improving these skeletal disorders.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Public review):</bold></p>
<p>Summary:</p>
<p>In this study, Zhang et al. reported that CHMP5 restricts bone formation by controlling endolysosomemitochondrion-mediated cell senescence. The effects of CHMP5 on osteoclastic bone resorption and bone turnover have been reported previously (PMID: 26195726), in which study the aberrant bone phenotype was observed in the CHMP5-ctsk-CKO mouse model, using the same mouse model, Zhang et al., report a novel role of CHMP5 on osteogenesis through affecting cell senescence. Overall, it is an interesting study and provides new insights in the field of cell senescence and bone.</p>
<p>Strengths:</p>
<p>Analyzed the bone phenotype OF CHMP5-periskeletal progenitor-CKO mouse model and found the novel role of senescent cells on osteogenesis and migration.</p>
<p>Weaknesses:</p>
<p>(1) There are a lot of papers that have reported that senescence impairs osteogenesis of skeletal stem cells. In this study, the author claimed that Chmp5 deficiency induces skeletal progenitor cell senescence and enhanced osteogenesis. Can the authors explain the controversial results?</p>
</disp-quote>
<p>Different skeletal stem cell populations in time and space have been identified and reported [2-6]. The present study shows that <italic>Chmp5</italic> deficiency in periskeletal (<italic>Ctsk</italic>-Cre) and endosteal (<italic>Dmp1</italic>-Cre) osteogenic cells causes cell senescence and aberrant bone formation. Although cell senescence during aging can impair the osteogenesis of marrow stromal cells (MSCs), which contributes to diseases with low bone mass such as osteoporosis, aging can also increase heterotopic ossification or mineralization in musculoskeletal soft tissues such as ligaments and tendons [7]. Notably, the abnormal periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was mainly mapped to insertion sites of tendons and ligaments on the bone (Fig. 1A and E), consistent with changes during aging. More broadly, aging can also cause abnormal ossification or mineralization in other body tissues, such as the heart valve [8, 9]. These different results reflect an aberrant state of ossification or mineralization in musculoskeletal tissues and throughout the body during aging. Based on the reviewer’s comment, we have discussed these results in the revised manuscript. Specifically, we add the following paragraph (Lines 453-462 in the combined manuscript):</p>
<p>“Notably, aging is associated with decreased osteogenic capacity in marrow stromal cells, which is related to conditions with low bone mass, such as osteoporosis. Rather, aging is also accompanied by increased ossification or mineralization in musculoskeletal soft tissues, such as tendons and ligaments [7]. In particular, the abnormal periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was predominantly mapped to insertion sites of tendons and ligaments on the bone (Fig. 1A and E), which is consistent with changes during aging and suggests that mechanical stress at these sites could contribute to the aberrant bone growth. These results suggest that skeletal stem/progenitor cells at different sites of musculoskeletal tissues could demonstrate different, even opposite outcomes in osteogenesis, due to cell senescence.”</p>
<disp-quote content-type="editor-comment">
<p>(2) Co-culture of Chmp5-KO periskeletal progenitors with WT ones should be conducted to detect the migration and osteogenesis of WT cells in response to Chmp5-KO-induced senescent cells. In addition, the co-culture of WT periskeletal progenitors with senescent cells induced by H2O2, radiation, or from aged mice would provide more information.</p>
</disp-quote>
<p>In the present study, the increased proliferation and osteogenesis of CD45-;CD31-;GFP- periskeletal progenitors were shown as paracrine mechanisms of <italic>Chmp5</italic>-deficient periskeletal progenitors to promote bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Figs. 4F, G, and S4C-E). According to the reviewer’s suggestion, we have carried out the coculture experiment and the coculture of <italic>Chmp5<sup>Ctsk</sup></italic> with <italic>wild-type</italic> skeletal progenitors could promote osteogenesis of <italic>wild-type</italic> cells (Fig. S4B), which further supports the paracrine effect of <italic>Chmp5</italic>-deficient periskeletal progenitors.</p>
<p>In addition, the cause and outcome of cell senescence could be highly heterogeneous, and different causes of cell senescence can cause significantly distinct, even opposite outcomes. Although the coculture experiments of WT periskeletal progenitors with senescent cells induced by H2O2, radiation, or from aged mice are very interesting, these are beyond the scope of the current study.</p>
<disp-quote content-type="editor-comment">
<p>(3) Many EVs were secreted from Chmp5-deleted periskeletal progenitors, compared to the rarely detected EVs around WT cells. Since EVs of BMSCs or osteoprogenitors show strong effects of promoting osteogenesis, did the EVs contribute to the enhanced osteogenesis induced by Chmp5defeciency? Author’s response:</p>
</disp-quote>
<p>This is an interesting question. Although we did not separately test the effect of EVs from <italic>Chmp5</italic>-deficient periskeletal progenitors on the osteogenesis of WT skeletal progenitors, the CD45-;CD31-;GFP- skeletal progenitor cells from <italic>Chmp5<sup>Ctsk</sup></italic> mice have an increased capacity of osteogenesis compared to corresponding cells from control animals (Figs. 4G and S4D). Also, the coculture of <italic>Chmp5</italic>-deficient with <italic>wild-type</italic> skeletal progenitors could enhance the osteogenesis of <italic>wild-type</italic> cells (Fig. S4B). These results suggest that EVs from <italic>Chmp5</italic>-deficient periskeletal progenitors could promote osteogenesis of neighboring WT skeletal progenitors. The specific functions of EVs of <italic>Chmp5</italic>-deficient periskeletal progenitors in regulating osteogenesis will be further investigated in future studies.</p>
<disp-quote content-type="editor-comment">
<p>(4) EVs secreted from senescent cells propagate senescence and impair osteogenesis, why do EVs secreted from senescent cells induced by Chmp5-defeciency have opposite effects on osteogenesis?</p>
</disp-quote>
<p>The question is similar to comments #1 and #3 from this reviewer. First, the manifestations (including the secretory phenotype) and outcomes of cell senescence could be highly heterogeneous depending on inducers, tissue and cell contexts, and other factors such as “time”. Different causes of cell senescence could lead to different manifestations and outcomes, which have been discussed in the manuscript (Lines 381-383). Similarly, as mentioned above, skeletal stem/progenitor cells at different sites of musculoskeletal tissues could also demonstrate distinct, even opposite outcomes, as a result of cell senescence (Line 453-462). Second, CD45-;CD31-;GFP- periskeletal progenitor cells from <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice have an increased capacity of proliferation and osteogenesis compared to corresponding cells from control animals (Figs. 4F, G and S4C-E). Furthermore, the conditioned medium of <italic>Chmp5</italic>-deficient skeletal progenitors promoted the proliferation of ATDC5 cells (Fig. 4E) and the coculture of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors could enhance the osteogenesis of <italic>wild-type</italic> cells (Fig. S4B). Taken together, these results show paracrine actions of <italic>Chmp5</italic>-deficient periskeletal progenitors in promoting aberrant bone growth in <italic>Chmp5</italic> conditional knockout mice. We also refer the reviewer to our responses to comments #1 and #3.</p>
<disp-quote content-type="editor-comment">
<p>(5) The Chmp5-ctsk mice show accelerated aging-related phenotypes, such as hair loss and joint stiffness. Did Ctsk also label cells in hair follicles or joint tissue?</p>
</disp-quote>
<p>This is an interesting question. Although we did not check the expression of CHMP5 in hair follicles, which is outside the scope of the present study, the result in Fig. 1E showed the expression of <italic>Ctsk</italic> in joint ligaments, tendons, and their insertion sites on the bone (Lines 108-111). Notably, the periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was mainly mapped to insertion sites of ligaments and tendons on the bone, which have been discussed in the revised manuscript (Lines 456-460).</p>
<disp-quote content-type="editor-comment">
<p>(6) Fifteen proteins were found to increase and five proteins to decrease in the cell supernatant of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors. How about SASP factors in the secretory profile?</p>
</disp-quote>
<p>The SASP phenotype and related factors of senescent cells could be highly heterogeneous depending on inducers, cell types, and timing of senescence [10, 11]. Most of the proteins we identified in the secretome analysis have previously been reported in the secretory profile of osteoblasts or involved in the regulation of osteogenesis. Although we were interested in changes in common SASP factors, such as cytokines and chemokines, the experiment did not detect these factors, probably due to their small molecular weights and the technical limitations of the mass-spec analysis. We have clarified this in the revised manuscript. Specifically, we add the following sentences (Lines 258-261):</p>
<p>“Notably, the secretome analysis did not detect common SASP factors, such as cytokines and chemokines, in the secretory profile of <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors, probably due to their small molecular weights and the technical limitations of the mass-spec analysis.”</p>
<disp-quote content-type="editor-comment">
<p>(7) D+Q treatment mitigates musculoskeletal pathologies in Chmp5 conditional knockout mice. In the previously published paper (CHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts), inhibition of osteoclastic bone resorption rescues the aberrant bone phenotype of the Chmp5 conditional knockout mice. Whether the effects of D+Q on bone overgrowth is because of the inhibition of bone resorption?</p>
</disp-quote>
<p>This is an important question. We have discussed the potential off-target effect of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice in the revised manuscript. Specifically, we add the following paragraph (Lines 441451):</p>
<p>“Furthermore, it is unclear whether the effect of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice involves targeting osteoclasts other than osteogenic cells, as osteoclast senescence has not yet been evaluated. However, the efficacy of Q + D in targeting osteogenic cells, which is the focus of the current study, was confirmed in <italic>Chmp5<sup>Dmp1</sup></italic> mice (Fig. 5C-E). Additionally, Q + D caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors in ex vivo culture (Fig. 5A), demonstrating the effectiveness of Q + D in targeting osteogenic cells in the <italic>Chmp5<sup>Ctsk</sup></italic> model. Furthermore, an alternative senolytic drug ABT-263 could also ameliorate periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Fig. 5F). Together, these results confirm that osteogenic cell senescence is responsible for the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice and senolytic treatments are effective in alleviating these skeletal disorders.”</p>
<disp-quote content-type="editor-comment">
<p>(8) The role of VPS4A in cell senescence should be measured to support the conclusion that CHMP5 regulates osteogenesis by affecting cell senescence.</p>
</disp-quote>
<p>We thank the reviewer for this suggestion. The current study mainly reports the function of CHMP5 in the regulation of skeletal progenitor cell senescence and osteogenesis. The roles of VPS4A in cell senescence and skeletal biology will be further explored in future studies. We have discussed this in the revised manuscript. Specifically, we add the following sentence (Lines 407-409):</p>
<p>“The roles of VPS4A in regulating musculoskeletal biology and cell senescence should be further explored in future studies.”</p>
<disp-quote content-type="editor-comment">
<p>(9) Cell senescence with markers, such as p21 and H2AX, co-stained with GFP should be performed in the mouse models to indicate the effects of Chmp5 on cell senescence in vivo.</p>
</disp-quote>
<p>According to the reviewer’s suggestion, we have already performed immunostaining of γH2AX and colocalization with GFP in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> and <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice. The results showed that there are more γH2AX+;GFP+ cells in the periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice compared to the periosteum of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> control animals. Because the γH2AX staining could stand as one of the critical results supporting the senescent phenotype of <italic>Chmp5</italic>-deficient periskeletal progenitors. We have added these results to Fig. 3E and put Fig. 3F in the original manuscript into Fig. S3E due to the space limitation in Figure 3. In sum, these results further enrich the senescent manifestations of <italic>Chmp5</italic>-deficient periskeletal progenitors.</p>
<disp-quote content-type="editor-comment">
<p>(10) ADTC5 cell as osteochondromas cells line, is not a good cell model of periskeletal progenitors.</p>
<p>Maybe primary periskeletal progenitor cell is a better choice.</p>
</disp-quote>
<p>ATDC5 cells are typically used as a chondrocyte progenitor cell line. However, our previous study showed that ATDC5 cells could also be used as a reasonable cell model for periskeletal progenitors [12], which was mentioned in the manuscript (Lines 202-204). In addition, the results of ATDC5 cells were also verified in primary periskeletal progenitor cells in this study.</p>
<disp-quote content-type="editor-comment">
<p><bold>Recommendations for the authors:</bold></p>
<p><bold>Reviewer #1 (Recommendations for the authors):</bold></p>
<p>Despite the robust experimental framework and intriguing findings, there are several areas that require further attention to enhance the manuscript's overall quality and clarity:</p>
<p>(1) The manuscript could benefit from a more in-depth discussion of the tissue-specific roles of CHMP5, particularly in addressing why CHMP5 deficiency results in distinct outcomes in osteogenic cells as opposed to other cell types, such as osteoclasts. Expanding the discussion would greatly enhance the comprehensiveness and clarity of the manuscript.</p>
</disp-quote>
<p>Based on the reviewer’s suggestion, we have expanded the discussion of the distinct roles of CHMP5 in different cell types. Specifically, we state (Lines 433-439):</p>
<p>“Also, a previous study by Adoro et al. did not detect endolysosomal abnormalities in _Chmp5_deficient developmental T cells [1]. Since both osteoclasts and T cells are of hematopoietic origin, and meanwhile osteogenic cells and MEFs, which show endolysosomal abnormalities after CHMP5 deficiency, are of mesenchymal origin, it turns out that the function of CHMP5 in regulating the endolysosomal pathway could be cell lineage-specific, which remains clarified in future studies.”</p>
<disp-quote content-type="editor-comment">
<p>(2) Given that Figures 1 and 2 suggest that the absence of Chmp5 (CHMP5Ctsk &amp; CHMP5Dmp1) leads to disordered proliferation or mineralization of bone or osteoblasts, the manuscript should delve deeper into the potential links between these findings and aging-related processes, such as age-associated fibrosis. Providing clearer explanations and discussion on these connections would help present a more cohesive understanding of the results in the context of aging.</p>
</disp-quote>
<p>We thank the reviewer for this favorable suggestion. A feature of aging is heterotopic ossification or mineralization in musculoskeletal soft tissues, including tendons and ligaments [7]. Notably, the abnormal periskeletal bone formation in <italic>Chmp5<sup>Ctsk</sup></italic> mice in this study was mostly mapped to the insertion sites of tendons and ligaments on the bone (Fig. 1A and E), which is consistent with changes during aging and suggests that mechanical stress at these sites could be a contributor to periskeletal overgrowth. We have discussed these results in the revised manuscript. Specifically, we add the following paragraph (Lines 453-462):</p>
<p>“Notably, aging is associated with decreased osteogenic capacity in marrow stromal cells, which is related to conditions with low bone mass, such as osteoporosis. Rather, aging is also accompanied by increased ossification or mineralization in musculoskeletal soft tissues, such as tendons and ligaments [7]. In particular, the abnormal periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was predominantly mapped to the insertion sites of tendons and ligaments on the bone (Fig. 1A and E), which is consistent with changes during aging and suggests that mechanical stress at these sites could contribute to the aberrant bone growth. These results suggest that skeletal stem/progenitor cells at different sites of musculoskeletal tissues could demonstrate different, even opposite outcomes in osteogenesis, due to cell senescence.”</p>
<disp-quote content-type="editor-comment">
<p>(3) The manuscript would be improved by a more refined analysis in Figures 3 and 5, particularly in relation to the use of senolytic drugs. Furthermore, a detailed discussion of the specificity and potential off-target effects of quercetin and dasatinib treatments in Chmp5-deficient mice would strengthen the therapeutic claims of these drugs.</p>
</disp-quote>
<p>In Figure 3, we have added additional experiments and results to strengthen the senescent phenotypes of <italic>Chmp5</italic>-deficient periskeletal progenitors, including significant enrichment of the SAUL_SEN_MAYO geneset (positively correlated with cell senescence) and the KAMMINGA_SENESCENCE geneset (negatively correlated with cell senescence) at the transcriptional level by GSEA analysis of RNA-seq data (Fig. S3F), and an increase of γH2AX+;GFP+ cells at the site of periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice compared to the periosteum of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> control mice (Fig. 3E). These results further enrich the senescent molecular manifestations of <italic>Chmp5</italic>-deficient periskeletal progenitors.</p>
<p>In Figure 5, we used an alternative senolytic drug ABT-263 to treat <italic>Chmp5<sup>Ctsk</sup></italic> mice, and this antisenescence treatment could also alleviate periskeletal bone overgrowth in this mouse model (Fig. 5F). Furthermore, we have also discussed the potential off-target effects of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice. Specifically, we add the following paragraph (Lines 441-451):</p>
<p>“Furthermore, it is unclear whether the effect of senolytic drugs in <italic>Chmp5<sup>Ctsk</sup></italic> mice involves targeting osteoclasts other than osteogenic cells, as osteoclast senescence has not yet been evaluated. However, the efficacy of Q + D in targeting osteogenic cells, which is the focus of the current study, was confirmed in <italic>Chmp5<sup>Dmp1</sup></italic> mice (Fig. 5C-E). Additionally, Q + D caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> compared to <italic>wild-type</italic> periskeletal progenitors in ex vivo culture (Fig. 5A), demonstrating the effectiveness of Q + D in targeting osteogenic cells in the <italic>Chmp5<sup>Ctsk</sup></italic> model. Furthermore, an alternative senolytic drug ABT-263 could also ameliorate periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice (Fig. 5F). Together, these results confirm that osteogenic cell senescence is responsible for the bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice and senolytic treatments are effective in alleviating these skeletal disorders.”</p>
<disp-quote content-type="editor-comment">
<p>(4) The manuscript could be further enhanced by providing more details into how CHMP5 specifically regulates VPS4A protein levels. Notably, this is a central aspect of the paper linking CHMP5 to endolysosomal dysfunction.</p>
</disp-quote>
<p>We thank the reviewer for this important suggestion. One of the novel findings of this study is that CHMP5 regulates the protein level of VPS4A without affecting its RNA transcription. The mechanism of CHMP5 in the regulation of VPS4A protein will be reported in a separate study. However, we have discussed the potential mechanism in the manuscript (Lines 399-409). Specifically, we state:</p>
<p>“However, the mechanism of CHMP5 in the regulation of the VPS4A protein has not yet been studied. Since CHMP5 can recruit the deubiquitinating enzyme USP15 to stabilize IκBα in osteoclasts by suppressing ubiquitination-mediated proteasomal degradation [13], it is also possible that CHMP5 stabilizes the VPS4A protein by recruiting deubiquitinating enzymes and regulating the ubiquitination of VPS4A, which needs to be clarified in future studies. Notably, mutations in the <italic>VPS4A</italic> gene in humans can cause multisystemic diseases, including musculoskeletal abnormalities [14] (OMIM: 619273), suggesting that normal expression and function of VPS4A are important for musculoskeletal physiology. The roles of VPS4A in regulating musculoskeletal biology and cell senescence should be further explored in future studies.”</p>
<disp-quote content-type="editor-comment">
<p>(5) The discussion section could be enriched by more thoroughly integrating the current findings with previous studies on CHMP5, particularly those exploring its role in osteoclast differentiation and NF-κB signaling.</p>
</disp-quote>
<p>The comment is similar to comment #1 of this reviewer. We have expanded the discussion of the distinct functions of CHMP5 in osteoclasts and osteogenic cells (Lines 424-439). We also refer the reviewer to our response to comment #1.</p>
<disp-quote content-type="editor-comment">
<p>(6) Figure S4 D is incorrectly arranged and should be revised accordingly.</p>
</disp-quote>
<p>Sorry for the confusion. We have added additional annotations to make the images clearer. Now it is Fig. S4E in the revised manuscript.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations for the authors):</bold></p>
<p>(1) Abstract A clinical perspective or at least an outline is desirable.</p>
</disp-quote>
<p>The clinical importance of the findings of this study in understanding and treating musculoskeletal disorders of lysosomal storage diseases has been highlighted at the end of the abstract (Line 38).</p>
<disp-quote content-type="editor-comment">
<p>(2) Introduction Header missing.</p>
<p>The protein name is BCL2, not Bcl2.</p>
</disp-quote>
<p>These have been corrected in the revised manuscript (Lines 41, 66).</p>
<disp-quote content-type="editor-comment">
<p>(3) Results</p>
<p>The mouse phenotype experiments are well done.</p>
<p>Hmga1, Hmga2, Trp53, Ets1, and Txn1 are no typical senescence-associated genes. How about</p>
<p>Cdkn2a and Cdkn1a? These could easily be highlighted in Figure 3B.</p>
</disp-quote>
<p>Hmga1, Hmga2, Trp53, Ets1, and Txn1 are within the geneset of Reactome Cellular Senescence. Notably, only the protein levels of CDKN2A (p16) and CDKN1A (p21) showed significant changes (Fig. 3D) and the mRNA levels of <italic>Cdkn2a</italic> and <italic>Cdkn1a</italic> did not show significant changes according to RNAseq data. We have added the result of <italic>Cdkn2a</italic> and <italic>Cdkn1a</italic> mRNA levels to Fig. S3D in the revised manuscript. Also, we add the following sentences in the text (Lines 193-195):</p>
<p>“However, the mRNA levels of <italic>Cdkn2a</italic> (p16) and <italic>Cdkn1a</italic> (p21) did not show significant changes according to the RNA-seq analysis (Fig. S3D).”</p>
<disp-quote content-type="editor-comment">
<p>Figure 3C: Which gene set was used for SASP?</p>
</disp-quote>
<p>The SASP geneset in Fig. 3C was from the Reactome database. We have clarified this in the figure legend of Fig. 3 in the revised manuscript (Line 1013).</p>
<disp-quote content-type="editor-comment">
<p>The symptom &quot;joint stiffness/contracture&quot; could also be due to skeletal abnormalities related to Chmp5Ctsk.</p>
</disp-quote>
<p>Joint stiffness/contracture during aging is mainly the result of heterotopic ossification or mineralization in musculoskeletal soft tissues, including ligaments, tendons, joint capsules, and their insertion sites on the bone. Notably, the periskeletal bone overgrowth in <italic>Chmp5<sup>Ctsk</sup></italic> mice was mainly mapped to the insertion sites of tendons, ligaments, and joint capsules on the bone, which are consistent with changes during aging. These results have been discussed in the revised manuscript (Lines 456-460).</p>
<disp-quote content-type="editor-comment">
<p>Overall, cellular senescence needs at least Cdkn2a and/or Cdkn1a and another marker, i.e. SenMayo or telomere-associated foci or senescence-associated distortion of satellites.</p>
</disp-quote>
<p>We have run GSEA with the SenMayo geneset and the result is added in Fig. S3F in the revised manuscript. Also, we ran another geneset KAMMINGA_SENESCENCE which includes genes downregulated in cell senescence. Both genesets are significantly enriched in <italic>Chmp5</italic>-deficient periskeletal progenitors based on RNA-seq data (Fig. S3F).</p>
<p>In addition, we also performed immunostaining for another senescence marker γH2AX and the results showed that there are more γH2AX+;GFP+ cells in periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>mTmG/+</sup></italic> mice compared to the periosteum of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> control animals (Fig. 3E).</p>
<p>Together, these results further support the senescent phenotypes of <italic>Chmp5</italic>-deficient periskeletal progenitors.</p>
<disp-quote content-type="editor-comment">
<p>For Figure 4A: What is the NES?</p>
</disp-quote>
<p>The value of NES has been added in Fig. 4A.</p>
<disp-quote content-type="editor-comment">
<p>The existence of vesicles does not necessarily indicate more SASP. Author’s response:</p>
</disp-quote>
<p>We agree with the reviewer that the secretion of extracellular vesicles is not directly correlated with the SASP. In this study, the increased secretory vesicles around <italic>Chmp5<sup>Ctsk</sup></italic> periskeletal progenitors represent a secretory phenotype of <italic>Chmp5</italic>-deficient periskeletal progenitors and have paracrine effects in the abnormal bone growth in <italic>Chmp5</italic> conditional knockout mice as shown in Figs. 4 and S4.</p>
<disp-quote content-type="editor-comment">
<p>The Chmp5-deficient cells COULD promote the proliferation and osteogenesis of other progenitors, but they might as well not. And if this is through the SASP, is completely unresolved.</p>
</disp-quote>
<p>CD45<sup>-</sup>;CD31<sup>-</sup>;GFP<sup>-</sup> periskeletal progenitor cells from <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice showed an increased capacity of proliferation and osteogenesis compared to the corresponding cells from control animals (Figs. 4F, G, and S4C-E). Also, the conditioned medium of <italic>Chmp5</italic>-deficient skeletal progenitors promoted the proliferation of ATDC5 cells (Fig. 4E). In addition, the coculture of <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>wild-type</italic> periskeletal progenitors could enhance the osteogenesis of <italic>wild-type</italic> cells (Fig. S4B). These results demonstrate the paracrine actions of <italic>Chmp5</italic>-deficient periskeletal progenitors in promoting aberrant bone growth in <italic>Chmp5<sup>Ctsk</sup></italic> and <italic>Chmp5<sup>Dmp1</sup></italic> mice. However, factors that mediate the paracrine effects of <italic>Chmp5</italic>-deficient periskeletal progenitors remain further clarified in future studies.</p>
<p>This has been mentioned in the revised manuscript (Lines 263-265).</p>
<disp-quote content-type="editor-comment">
<p>Figure 5C: The time points are not labelled.</p>
</disp-quote>
<p>The time point of 16 weeks was mentioned in the Method section and now it has been added in the legend of Fig. 5C (Line 1063).</p>
<disp-quote content-type="editor-comment">
<p>Figure B: Was the bone's overall thickness quantified?</p>
</disp-quote>
<p>In Fig. 5B, bone morphology in <italic>Chmp5<sup>Ctsk</sup></italic> mice is irregular and difficult to quantify. Therefore, we did not qualify the overall bone thickness in these animals. However, the thickness of the cortical bone was measured by micro-CT analysis in <italic>Chmp5<sup>Dmp1</sup></italic> mice after treatment with Q + D (Fig. 5E). Also, we have added the image of the gross femur thickness of <italic>Chmp5<sup>Dmp1</sup></italic> mice before and after treatment with Q + D in Fig. 5E.</p>
<disp-quote content-type="editor-comment">
<p>It needs to be demonstrated that the actual cell number was reduced after D+Q treatment.</p>
</disp-quote>
<p>The Q + D treatment caused a higher cell apoptotic ratio in <italic>Chmp5<sup>Ctsk</sup></italic> vs. <italic>wild-type</italic> skeletal progenitors in ex vivo culture (Fig. 5A), suggesting its effectiveness in targeting the senescent periskeletal progenitors.</p>
<disp-quote content-type="editor-comment">
<p>Figure 7A: What is the NES?</p>
</disp-quote>
<p>The value of NES has been added in Fig. 7A.</p>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #3 (Recommendations for the authors):</bold></p>
<p>(1) The WB analysis should be quantified in the Figure 3D.</p>
</disp-quote>
<p>In Fig. 3D, the numbers above the lanes of p16 and p21 are the results of the quantification of the band intensity after normalization by β-Actin, which has been indicated in the Figure legend (Lines 10151017).</p>
<disp-quote content-type="editor-comment">
<p>(2) The osteoblast detection should be measured with antibody against osteocalcin.</p>
</disp-quote>
<p>This comment did not specify what result the reviewer was referring to. However, most of the experiments in this study were performed in primary skeletal progenitor cells or cell lines. Osteoblasts were not specifically involved in the current study.</p>
<disp-quote content-type="editor-comment">
<p>(3) Co-culture of Chmp5-KO periskeletal progenitors with WT ones should be conducted to detect the migration and osteogenesis of WT cell in response to Chmp5-KO induced senescent cells. In addition, co-culture of WT periskeletal progenitors with senescent cells induced by H2O2, radiation, or from aged mice would provide more information.</p>
</disp-quote>
<p>This comment is the same as comment #2 in the Public Reviews of this Reviewer. We already carried out the coculture experiment of <italic>Chmp5</italic>-deficient and <italic>wild-type</italic> periskeletal progenitors and the result was added in Fig. S4B. We refer the reviewer to our response to comment #2 in the Public Reviews for more details.</p>
<disp-quote content-type="editor-comment">
<p>(4) D+Q treatment mitigates musculoskeletal pathologies in Chmp5 conditional knockout mice. In the previously published paper (CHMP5 controls bone turnover rates by dampening NF-κB activity in osteoclasts), inhibition of osteoclastic bone resorption rescues the aberrant bone phenotype of the Chmp5 conditional knockout mice. Is the effect of D+Q on bone overgrowth because of the inhibition of bone resorption?</p>
</disp-quote>
<p>This comment is the same as comment #7 in the Public Reviews of this Reviewer, where we already address this question.</p>
<disp-quote content-type="editor-comment">
<p>(5) The role of VPS4A in cell senescence should be measured to support the conclusion that CHMP5 regulates osteogenesis through affecting cell senescence.</p>
</disp-quote>
<p>This comment is the same as comment #8 in the Public Reviews of this Reviewer. We refer the reviewer to our response to that comment.</p>
<disp-quote content-type="editor-comment">
<p>(6) Cell senescence with the markers, such as p21 and H2AX, co-stained with GFP should be performed in the mouse models to indicate the effects of Chmp5 on cell senescence in vivo.</p>
</disp-quote>
<p>This comment is the same as comment #9 in the Public Reviews of this Reviewer. We have performed immunostaining of γH2AX and colocalization with GFP in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice and <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice. The results showed that there were more γH2AX+;GFP+ cells at the site of periskeletal overgrowth in <italic>Chmp5<sup>Ctsk</sup>;Rosa26<sup>26mTmG/+</sup></italic> mice compared to the periosteum of <italic>Chmp5<sup>Ctsk/+</sup>;Rosa26<sup>26mTmG/+</sup></italic> control mice (Fig. 3E). We also refer the reviewer to our response to comment #9 in Public Reviews.</p>
<disp-quote content-type="editor-comment">
<p>(7) ADTC5 cell as osteochondromas cells line, is not a good cell model of periskeletal progenitors.</p>
<p>Maybe primary periskeletal progenitor cell is a better choice.</p>
</disp-quote>
<p>This comment is the same as comment #10 in the Public Reviews of this Reviewer. Our previous study showed that ATDC5 cells could be used as a reasonable cell model for periskeletal progenitors [12]. Also, most of the results of ATDC5 cells in the current study were verified in primary periskeletal progenitors.</p>
<p>References</p>
<p>(1) Adoro S, Park KH, Bettigole SE, Lis R, Shin HR, Seo H, et al. Post-translational control of T cell development by the ESCRT protein CHMP5. Nat Immunol. 2017;18(7):780-90. doi: 10.1038/ni.3764. PubMed PMID: 28553951.</p>
<p>(2) Kassem M, Bianco P. Skeletal stem cells in space and time. Cell. 2015;160(1-2):17-9. doi: 10.1016/j.cell.2014.12.034. PubMed PMID: 25594172.</p>
<p>(3) Chan CKF, Gulati GS, Sinha R, Tompkins JV, Lopez M, Carter AC, et al. Identification of the Human Skeletal Stem Cell. Cell. 2018;175(1):43-56 e21. doi: 10.1016/j.cell.2018.07.029. PubMed PMID: 30241615.</p>
<p>(4) Debnath S, Yallowitz AR, McCormick J, Lalani S, Zhang T, Xu R, et al. Discovery of a periosteal stem cell mediating intramembranous bone formation. Nature. 2018;562(7725):133-9. Epub 20180924. doi: 10.1038/s41586-018-0554-8. PubMed PMID: 30250253; PubMed Central PMCID: PMCPMC6193396.</p>
<p>(5) Mizuhashi K, Ono W, Matsushita Y, Sakagami N, Takahashi A, Saunders TL, et al. Resting zone of the growth plate houses a unique class of skeletal stem cells. Nature. 2018;563(7730):254-8. doi: 10.1038/s41586-018-0662-5. PubMed PMID: 30401834; PubMed Central PMCID: PMCPMC6251707.</p>
<p>(6) Zhang F, Wang Y, Zhao Y, Wang M, Zhou B, Zhou B, et al. NFATc1 marks articular cartilage progenitors and negatively determines articular chondrocyte differentiation. Elife. 2023;12. Epub 20230215. doi: 10.7554/eLife.81569. PubMed PMID: 36790146; PubMed Central PMCID: PMCPMC10076019.</p>
<p>(7) Dai GC, Wang H, Ming Z, Lu PP, Li YJ, Gao YC, et al. Heterotopic mineralization (ossification or calcification) in aged musculoskeletal soft tissues: A new candidate marker for aging. Ageing Res Rev. 2024;95:102215. Epub 20240205. doi: 10.1016/j.arr.2024.102215. PubMed PMID: 38325754.</p>
<p>(8) Mohler ER, 3rd, Adam LP, McClelland P, Graham L, Hathaway DR. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol. 1997;17(3):547-52. doi: 10.1161/01.atv.17.3.547. PubMed PMID: 9102175.</p>
<p>(9) Mohler ER, 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001;103(11):1522-8. doi: 10.1161/01.cir.103.11.1522. PubMed PMID: 11257079.</p>
<p>(10) Paramos-de-Carvalho D, Jacinto A, Saude L. The right time for senescence. Elife. 2021;10. Epub 2021/11/11. doi: 10.7554/eLife.72449. PubMed PMID: 34756162; PubMed Central PMCID: PMCPMC8580479.</p>
<p>(11) Wiley CD, Campisi J. The metabolic roots of senescence: mechanisms and opportunities for intervention. Nat Metab. 2021;3(10):1290-301. Epub 2021/10/20. doi: 10.1038/s42255-021-00483-8. PubMed PMID: 34663974; PubMed Central PMCID: PMCPMC8889622.</p>
<p>(12) Ge X, Tsang K, He L, Garcia RA, Ermann J, Mizoguchi F, et al. NFAT restricts osteochondroma formation from entheseal progenitors. JCI Insight. 2016;1(4):e86254. doi: 10.1172/jci.insight.86254. PubMed PMID: 27158674; PubMed Central PMCID: PMCPMC4855520.</p>
<p>(13) Greenblatt MB, Park KH, Oh H, Kim JM, Shin DY, Lee JM, et al. CHMP5 controls bone turnover rates by dampening NF-kappaB activity in osteoclasts. J Exp Med. 2015;212(8):1283-301. Epub 20150720. doi: 10.1084/jem.20150407. PubMed PMID: 26195726; PubMed Central PMCID: PMCPMC4516796.</p>
<p>(14) Rodger C, Flex E, Allison RJ, Sanchis-Juan A, Hasenahuer MA, Cecchetti S, et al. De Novo VPS4A Mutations Cause Multisystem Disease with Abnormal Neurodevelopment. Am J Hum Genet. 2020;107(6):1129-48. Epub 20201112. doi: 10.1016/j.ajhg.2020.10.012. PubMed PMID: 33186545; PubMed Central PMCID: PMCPMC7820634.</p>
</body>
</sub-article>
</article>